2. 筋萎縮性側索硬化症 Disease details / Clinical trials / Drug dev / DR info

1.0 MIU IL-2 PER DAY
   Centre Hospitalier Universitaire de Nimes
      2015   Phase 2   NCT02059759   France
100% OF individual calory requirement
   University of Ulm
      2025   -   NCT06877143   Germany
100MG FHND1002
   Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.
      2024   Phase 1   NCT06782958   China
120% OF individual calory requirement
   University of Ulm
      2025   -   NCT06877143   Germany
150 MG FHND1002
   Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.
      2024   Phase 1   NCT06782958   China
18F-OP-801
   Ashvattha Therapeutics, Inc.
      2023   Phase 1/Phase 2   NCT05395624   United States
1H-pyrazol
   Ferrer Internacional S.A.
      2021   Phase 3   EUCTR2020-003376-40-IT   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom
2.0 MIU IL-2 PER DAY
   Centre Hospitalier Universitaire de Nimes
      2015   Phase 2   NCT02059759   France
250 MG CK-2017357
   Cytokinetics
      2010   Phase 2   NCT01089010   United States
250MG FHND1002
   Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.
      2024   Phase 1   NCT06782958   China
3k3A-APC protein
   Macquarie University, Australia
      2021   Phase 2   NCT05039268   Australia
4 cholesten-3-ONE, oxime
   TROPHOS
      2011   -   EUCTR2010-021179-10-GB   Germany;Spain;United Kingdom
4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]-benzamide, methane sulphonic acid salt. AB1010base
   AB SCIENCE
      2021   Phase 3   EUCTR2019-001862-13-IT   Argentina;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;Ukraine;United Kingdom;United States
4-cholesten-3-ONE, oxime
   TROPHOS
      2009   Phase 2;Phase 3   EUCTR2008-007320-25-GB   Belgium;France;Germany;Spain;United Kingdom
   TROPHOS SA
      2011   -   EUCTR2010-021179-10-DE   Germany;Spain;United Kingdom
      2011   Phase 2;Phase 3   EUCTR2010-021179-10-BE   Belgium;Germany;Spain;United Kingdom
      2009   Phase 2;Phase 3   EUCTR2008-007320-25-FR   Belgium;France;Germany;Spain;United Kingdom
      2009   Phase 2   EUCTR2008-007320-25-ES   Belgium;France;Germany;Spain;United Kingdom
      2009   -   EUCTR2008-007320-25-DE   Belgium;France;Germany;Spain;United Kingdom
      2009   Phase 2;Phase 3   EUCTR2008-007320-25-BE   Belgium;France;Germany;Spain;United Kingdom
40 MG GA
   TEVA Pharmaceutical Industries. Ltd.
      2006   Phase 2   EUCTR2006-001688-49-GB   Belgium;Germany;Italy;United Kingdom
      2006   -   EUCTR2006-001688-49-DE   Belgium;Germany;Italy;United Kingdom
      2006   -   EUCTR2006-001688-49-BE   Belgium;Germany;Italy;United Kingdom
40 MG glatiramer acetate
   TEVA Pharmaceutical Industries. Ltd.
      2006   Phase 2   EUCTR2006-001688-49-GB   Belgium;Germany;Italy;United Kingdom
      2006   -   EUCTR2006-001688-49-DE   Belgium;Germany;Italy;United Kingdom
      2006   -   EUCTR2006-001688-49-BE   Belgium;Germany;Italy;United Kingdom
5% glucose water solution
   Centre Hospitalier Universitaire de Nimes
      2017   Phase 2   NCT03039673   France;United Kingdom
500 MG CK-2017357
   Cytokinetics
      2010   Phase 2   NCT01089010   United States
50MG FHND1002
   Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.
      2024   Phase 1   NCT06782958   China
6-ethynyl-1-(pentan-3-YL)-1H-imidazo[4,5-B]pyrazin-2(3H)-ONE
   CYTOKINETICS, INC.
      2017   Phase 3   EUCTR2016-002629-13-IT   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2014-005413-23-IT   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States
   Cytokinetics Inc
      2013   -   EUCTR2012-004987-23-IE   Canada;Germany;Ireland;Netherlands;Spain;United Kingdom;United States
      2013   Phase 2   EUCTR2012-004987-23-GB   Canada;Germany;Ireland;Netherlands;Spain;United Kingdom;United States
      2013   Phase 2   EUCTR2012-004987-23-ES   Canada;France;Germany;Ireland;Netherlands;Spain;United Kingdom;United States
      2013   -   EUCTR2012-004987-23-DE   Canada;Germany;Ireland;Netherlands;Spain;United Kingdom;United States
      -   -   EUCTR2012-004987-23-NL   Canada;France;Germany;Ireland;Netherlands;Spain;United Kingdom;United States
   Cytokinetics, Inc.
      2017   Phase 3   EUCTR2016-002629-13-PT   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002629-13-NL   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002629-13-IE   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002629-13-GB   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002629-13-FR   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002629-13-ES   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002629-13-BE   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2014-005413-23-PT   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2014-005413-23-NL   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2014-005413-23-IE   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2014-005413-23-ES   Belgium;Canada;France;Germany;Ireland;Netherlands;Portugal;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2014-005413-23-DE   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2014-005413-23-BE   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States
      2015   Phase 3   EUCTR2014-005413-23-GB   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States
89ZR-DFO-AP-101
   Université de Sherbrooke
      2023   Phase 1   NCT05974579   Canada
9-CIS, 12-CIS-11,11-D2-linoleic acid ethyl ester
   Retrotope, Inc.
      2021   Phase 2   EUCTR2020-003962-38-SE   Estonia;Netherlands;Sweden
      2021   Phase 2   EUCTR2020-003962-38-NL   Estonia;Netherlands;Sweden
      2021   Phase 2   EUCTR2020-003962-38-EE   Estonia;Netherlands;Sweden
AB 1003
   AB SCIENCE
      2021   Phase 3   EUCTR2019-001862-13-IT   Argentina;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;Ukraine;United Kingdom;United States
AB1010
   AB SCIENCE
      2021   Phase 3   EUCTR2019-001862-13-IT   Argentina;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;Ukraine;United Kingdom;United States
      2015   Phase 2;Phase 3   EUCTR2010-024423-24-IT   Argentina;Colombia;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Netherlands;Portugal;Romania;Serbia;Slovakia;Spain;United Kingdom
   AB Science
      2022   Phase 3   EUCTR2019-001862-13-GR   Argentina;Belgium;Canada;Denmark;France;Greece;Ireland;Israel;Italy;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2019-001862-13-NO   Argentina;Belgium;Canada;Denmark;France;Greece;Ireland;Israel;Italy;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2019-001862-13-DK   Argentina;Belgium;Canada;Denmark;France;Greece;Ireland;Israel;Italy;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2019-001862-13-SE   Argentina;Belgium;Canada;Denmark;France;Greece;Ireland;Israel;Italy;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2019-001862-13-PL   Argentina;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;Ukraine;United Kingdom;United States
      -   Phase 3   EUCTR2019-001862-13-IE   Argentina;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;United Kingdom;United States
      -   Phase 3   EUCTR2019-001862-13-GB   Argentina;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;United Kingdom;United States
      -   Phase 2;Phase 3   EUCTR2010-024423-24-IE   Argentina;Belgium;Colombia;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Netherlands;Portugal;Romania;Slovakia;Spain;Switzerland;United Kingdom;United States
   ABScience
      2022   Phase 3   EUCTR2019-001862-13-PT   Argentina;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2019-001862-13-BE   Argentina;Belgium;Canada;Denmark;France;Greece;Ireland;Israel;Italy;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2019-001862-13-SI   Argentina;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2019-001862-13-FR   Argentina;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2019-001862-13-ES   Argentina;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;United Kingdom;United States
      2015   Phase 2;Phase 3   EUCTR2010-024423-24-PT   Argentina;Colombia;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Netherlands;Portugal;Romania;Serbia;Slovakia;Spain;United Kingdom;United States
      2015   Phase 2;Phase 3   EUCTR2010-024423-24-NL   Argentina;Colombia;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Netherlands;Portugal;Romania;Serbia;Slovakia;Spain;United Kingdom;United States
      2015   Phase 2;Phase 3   EUCTR2010-024423-24-HU   Argentina;Belgium;Colombia;Czech Republic;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Mexico;Netherlands;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Taiwan;United Kingdom;United States
      2015   Phase 2;Phase 3   EUCTR2010-024423-24-GR   Argentina;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;United States
      2014   Phase 2;Phase 3   EUCTR2010-024423-24-SK   Argentina;Colombia;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Netherlands;Portugal;Romania;Serbia;Slovakia;Spain;United Kingdom;United States
      2013   Phase 2   EUCTR2010-024423-24-ES   France;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain
Abacavir
   Macquarie University, Australia
      2024   Phase 3   NCT06658977   Australia
   Stichting TRICALS Foundation
      2023   Phase 3   EUCTR2020-005069-15-SI   Australia;Ireland;Netherlands;Slovenia;Spain;United Kingdom
      2022   Phase 3   EUCTR2020-005069-15-IE   Australia;Ireland;Netherlands;Slovenia;Spain;United Kingdom
      2021   Phase 3   EUCTR2020-005069-15-NL   Australia;Ireland;Netherlands;Slovenia;Spain;United Kingdom
Abatacept
   The Methodist Hospital Research Institute
      2021   Phase 1   NCT06307301   United States
ABBV-CLS-7262
   Merit E. Cudkowicz, MD
      2020   Phase 2/Phase 3   NCT04297683   United States
ABBV-CLS-7262 dose 1
   Merit E. Cudkowicz, MD
      2023   Phase 2/Phase 3   NCT05740813   United States
ABBV-CLS-7262 dose 2
   Merit E. Cudkowicz, MD
      2023   Phase 2/Phase 3   NCT05740813   United States
Acetyl-L-carnitine
   Mario Negri Institute for Pharmacological Research
      2025   Phase 2/Phase 3   NCT06126315   -
Acetylcarnitine
   IST. DI RICERCHE FARMACOLOG. M. NEGRI
      2005   -   EUCTR2004-004158-23-IT   Italy
Acido tauroursodesossicolico
   IRCCS ISTITUTO CLINICO HUMANITAS
      2018   Phase 3   EUCTR2018-002722-22-IT   Belgium;France;Germany;Ireland;Italy;Netherlands;United Kingdom
Acthar
   Mallinckrodt
      2017   Phase 2/Phase 3   NCT03068754   Argentina;Canada;Chile;Colombia;Mexico;Peru;United States
Active treatment with dual therapy
   El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez
      2016   Phase 2   NCT03204500   Mexico
Actos 15 MG
   University Hospital of Ulm
      2008   -   EUCTR2006-005410-13-DE   Germany
Actos 30 MG
   University Hospital of Ulm
      2008   -   EUCTR2006-005410-13-DE   Germany
Actos 45 MG
   University Hospital of Ulm
      2008   -   EUCTR2006-005410-13-DE   Germany
AL001
   Alector Inc.
      2021   Phase 2   NCT05053035   United States
Albumin
   Instituto Grifols, S.A.
      2014   Phase 2   NCT02479802   Spain
ALBúmina humana
   Instituto Grifols S.A.
      2014   Phase 4   EUCTR2013-004842-40-ES   Spain
Aldesleukin
   The Methodist Hospital Research Institute
      2021   Phase 1   NCT06307301   United States
Aleeto
   Beijing Tiantan Hospital
      2023   Phase 1   NCT06181526   China
ALL-P-AMBO-2'-O-(2-methoxyethyl)-P-thioguanylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methylcytidylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)adenylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)adenylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methyluridylyl-(3'-O->5'-O)-2'-deoxy-P-thioguanylyl-(3'-O->5'-O)-P-thiothymidylyl-(3'-O->5'-O)-2'-deoxy-5-methyl-P-thiocytidylyl-(3'-O->5'-O)-2'-deoxy-P-thioadenylyl-(3'-O->5'-O)-2'-deoxy-5-methyl-P-thiocytidylyl-(3'-O->5'-O)-2'-deoxy-5-methyl-P-thiocytidylyl-(3'-O->5'-O)-P-thiothymidylyl-(3'-O->5'-O)-P-thiothymidylyl-(3'-O->5'-O)-P-thiothymidylyl-(3'-O->5'-O)-2'-deoxy-5-methyl-P-thiocytidylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)adenylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methyluridylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-P-thioadenylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methylcytidine
   Ionis Pharmaceuticals, Inc.
      2022   Phase 1;Phase 2;Phase 3   EUCTR2020-005522-28-NL   Belgium;Brazil;Canada;France;Germany;Ireland;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Poland;Spain;Sweden;Turkey;United Kingdom;United States
      2021   Phase 1;Phase 2;Phase 3   EUCTR2020-005522-28-BE   Belgium;Brazil;Canada;Germany;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      -   Phase 1;Phase 2;Phase 3   EUCTR2020-005522-28-SE   Belgium;Brazil;Canada;Germany;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
      -   Phase 1;Phase 2;Phase 3   EUCTR2020-005522-28-PL   Belgium;Brazil;Canada;Germany;Ireland;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      -   Phase 1;Phase 2;Phase 3   EUCTR2020-005522-28-IE   Belgium;Brazil;Canada;Germany;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
      -   Phase 1;Phase 2;Phase 3   EUCTR2020-005522-28-DE   Belgium;Brazil;Canada;France;Germany;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
Allorx
   The Foundation for Orthopaedics and Regenerative Medicine
      2025   Phase 1   NCT05003921   Antigua and Barbuda
ALN-SOD
   Regeneron Pharmaceuticals
      2024   Phase 1   NCT06351592   Canada;Japan;Korea, Republic of
Alpha-lipoic acid
   AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO
      2006   -   EUCTR2005-005152-40-IT   Italy
ALS patients epidemiological caracterization
   Conde, Bebiana, M.D.
      2016   -   NCT03073239   Portugal
ALS patients genetic characterization
   Conde, Bebiana, M.D.
      2016   -   NCT03073239   Portugal
ALXN1210
   ALEXION PHARMACEUTICALS INCORPORATED
      2020   Phase 3   EUCTR2019-004619-30-IT   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
   Alexion Pharmaceuticals
      2020   Phase 3   EUCTR2019-004619-30-SE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004619-30-NL   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004619-30-IE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004619-30-GB   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004619-30-FR   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004619-30-ES   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004619-30-DK   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004619-30-DE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
Amantadine hydrochloride oral solution
   University of Edinburgh
      2020   Phase 2/Phase 3   NCT04302870   United Kingdom
Ambroxol
   The Florey Institute of Neuroscience and Mental Health
      2023   Phase 2   NCT05959850   Australia
AMDX2011P
   Amydis Inc.
      2022   Phase 1/Phase 2   NCT05542576   United States
Amivita
   Wujin People's Hospital
      2017   -   NCT03103815   China
Amsc
   Bioinova, s.r.o.
      2012   Phase 2   EUCTR2011-000362-35-CZ   Czech Republic
AMT-162
   UniQure Biopharma B.V.
      2024   Phase 1/Phase 2   NCT06100276   United States
AMX0035
   AMYLYX PHARMACEUTICALS Inc.
      2022   Phase 3   EUCTR2022-002348-33-IT   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2021   Phase 3   EUCTR2021-000250-26-IT   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
   Amylyx Pharmaceuticals Inc.
      2023   Phase 3   EUCTR2022-002348-33-PT   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2023   Phase 3   EUCTR2022-002348-33-PL   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2023   Phase 3   EUCTR2022-002348-33-FR   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2023   Phase 3   EUCTR2022-002348-33-BE   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2022   Phase 3   NCT05619783   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2022   -   NCT05286372   Puerto Rico;United States
      2022   Phase 3   EUCTR2022-002348-33-NL   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2022   Phase 3   EUCTR2022-002348-33-ES   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-000250-26-PT   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-000250-26-PL   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-000250-26-BE   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2021   Phase 3   NCT05021536   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Puerto Rico;Spain;Sweden;United Kingdom;United States
      2021   Phase 3   EUCTR2021-000250-26-SE   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2021   Phase 3   EUCTR2021-000250-26-NL   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2021   Phase 3   EUCTR2021-000250-26-FR   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2021   Phase 3   EUCTR2021-000250-26-ES   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2021   Phase 3   EUCTR2021-000250-26-DE   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2020   Phase 2/Phase 3   NCT04516096   United States
      2018   Phase 2   NCT03488524   United States
      2017   Phase 2   NCT03127514   United States
AMX0114
   Amylyx Pharmaceuticals Inc.
      2025   Phase 1   NCT06665165   Canada
Amyotrophic lateral sclerosis functional rating scale-revised
   University of Florida
      2016   Early Phase 1   NCT02710162   United States
Anakinra
   Charite University, Berlin, Germany
      2011   Phase 2   NCT01277315   Germany
ANTI-(misfolded human superoxide dismutase 1) human IGG1m3 monoclonal antibody
   AL-S Pharma, AG
      2021   Phase 2   EUCTR2020-005971-11-SE   Belgium;Canada;Germany;Korea, Republic of;Sweden;United States
      2021   Phase 2   EUCTR2020-005971-11-DE   Belgium;Canada;Germany;Korea, Republic of;Sweden;United States
   AL-S Pharma, SA
      2023   Phase 2   EUCTR2020-005971-11-BE   Belgium;Canada;Germany;Korea, Republic of;Sweden;United States
ANX005
   Annexon Biosciences
      2021   Phase 2   EUCTR2021-000325-26-FR   Canada;France;United States
   Annexon, Inc.
      2021   Phase 2   NCT04569435   Canada;France;United States
AP-101
   AL-S Pharma
      2021   Phase 2   NCT05039099   Belgium;Canada;Germany;Korea, Republic of;Sweden;United States
      2019   Phase 1   NCT03981536   Canada
   AL-S Pharma, AG
      2021   Phase 2   EUCTR2020-005971-11-SE   Belgium;Canada;Germany;Korea, Republic of;Sweden;United States
      2021   Phase 2   EUCTR2020-005971-11-DE   Belgium;Canada;Germany;Korea, Republic of;Sweden;United States
   AL-S Pharma, SA
      2023   Phase 2   EUCTR2020-005971-11-BE   Belgium;Canada;Germany;Korea, Republic of;Sweden;United States
APL-2
   APELLIS PHARMACEUTCIALS, INC.
      2021   Phase 2   EUCTR2019-003797-10-IT   Argentina;Australia;Belgium;Brazil;Czech Republic;Czechia;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States
   Apellis Pharmaceuticals, Inc.
      2021   Phase 2   EUCTR2019-003797-10-NL   Argentina;Australia;Belgium;Brazil;Czech Republic;Czechia;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States
      2021   Phase 2   EUCTR2019-003797-10-IE   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Czechia;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States
      2021   Phase 2   EUCTR2019-003797-10-DE   Argentina;Australia;Belgium;Brazil;Czech Republic;Czechia;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States
      2021   Phase 2   EUCTR2019-003797-10-CZ   Argentina;Australia;Belgium;Brazil;Czech Republic;Czechia;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States
      2020   Phase 2   NCT04579666   Australia;Belgium;Czechia;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States
APO-P001
   Apodemus AB
      2014   Phase 2   EUCTR2012-002099-15-SE   Sweden
ARGX-119
   argenx
      2024   Phase 2   NCT06441682   Belgium;Canada;Denmark;France;Netherlands;Sweden
Arimoclomol
   CytRx
      2008   Phase 2   NCT00561366   Canada;United States
      2005   Phase 2   NCT00244244   United States
   ORPHAZYME APS
      2019   Phase 3   EUCTR2019-000374-39-IT   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2018   Phase 3   EUCTR2018-000137-13-IT   Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
   Orphazyme A/S
      2019   Phase 3   EUCTR2019-000374-39-SE   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2019-000374-39-PL   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2019-000374-39-NL   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2019-000374-39-GB   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2019-000374-39-ES   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2019-000374-39-DE   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2018   Phase 3   EUCTR2018-000137-13-SE   Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2018   Phase 3   EUCTR2018-000137-13-PL   Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2018   Phase 3   EUCTR2018-000137-13-NL   Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2018   Phase 3   EUCTR2018-000137-13-GB   Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2018   Phase 3   EUCTR2018-000137-13-FR   Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2018   Phase 3   EUCTR2018-000137-13-ES   Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2018   Phase 3   EUCTR2018-000137-13-BE   Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
   University of Miami
      2009   Phase 2/Phase 3   NCT00706147   United States
   ZevraDenmark
      2019   Phase 3   NCT03836716   Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2018   Phase 3   NCT03491462   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
ARO-SOD1 injection
   Arrowhead Pharmaceuticals
      2024   Phase 1   NCT05949294   -
Arundic acid
   ONO Pharmaceutical Co., Ltd.
      2008   -   EUCTR2007-004723-37-GB   Belgium;France;Germany;United Kingdom
      2008   Phase 2   EUCTR2007-004723-37-FR   Belgium;France;Germany;United Kingdom
      2008   -   EUCTR2007-004723-37-DE   Belgium;France;Germany;United Kingdom
      2008   -   EUCTR2007-004723-37-BE   Belgium;France;Germany;United Kingdom
   ONO Pharmaceutical Co.,Ltd
      2007   -   EUCTR2006-002660-26-NL   Austria;Belgium;France;Germany;Italy;Netherlands;United Kingdom
      2007   -   EUCTR2006-002660-26-GB   Austria;Belgium;France;Germany;Italy;Netherlands;United Kingdom
      2006   Phase 2   EUCTR2006-002660-26-FR   Austria;Belgium;France;Germany;Italy;Netherlands;United Kingdom
      2006   -   EUCTR2006-002660-26-DE   Austria;Belgium;France;Germany;Italy;Netherlands;United Kingdom
      2006   -   EUCTR2006-002660-26-BE   Austria;Belgium;France;Germany;Italy;Netherlands;United Kingdom
      2006   -   EUCTR2006-002660-26-AT   Austria;Belgium;France;Germany;Italy;Netherlands;United Kingdom
Aspaveli
   Apellis Pharmaceuticals, Inc.
      2021   Phase 2   EUCTR2019-003797-10-NL   Argentina;Australia;Belgium;Brazil;Czech Republic;Czechia;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States
      2021   Phase 2   EUCTR2019-003797-10-IE   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Czechia;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States
      2021   Phase 2   EUCTR2019-003797-10-DE   Argentina;Australia;Belgium;Brazil;Czech Republic;Czechia;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States
Astaxanthin
   Duke University
      2024   Phase 2   NCT06429059   United States
Astrorx
   Kadimastem
      2018   Phase 1/Phase 2   NCT03482050   Israel
Autologous adipose-derived mesenchymal stromal cells
   Mayo Clinic
      2017   Phase 2   NCT03268603   United States
Autologous adult bone marrow mononuclear cells (BM-MNC) unexpanded
   Fundación para la Formación e Investigación Sanitarias de la Región de Murcia
      2019   Phase 2   EUCTR2019-002302-46-ES   Spain
Autologous adult bone marrow mononuclear cells unexpanded
   Fundación para la Formación e Investigación Sanitarias de la Región de Murcia
      2019   Phase 2   EUCTR2019-002302-46-ES   Spain
Autologous bone marrow mononucleated cells
   Fundación Sanitaria para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO)
      2014   -   EUCTR2011-004801-25-ES   Spain
Autologous bone marrow-derived stem cells
   TCA Cellular Therapy
      2010   Phase 1   NCT01082653   United States
Autologous mesenchymal stem cells
   Hospital e Maternidade Dr. Christóvão da Gama
      2015   Phase 1   NCT02987413   Brazil
   Mayo Clinic
      2012   Phase 1   NCT01609283   United States
      2010   Phase 1   NCT01142856   United States
Autologous MSC-NTF cells
   Brainstorm-Cell Therapeutics
      2014   Phase 2   NCT02017912   United States
Autologous T-regulatory lymphocytes
   Stanley H. Appel, MD
      2016   Phase 1   NCT03241784   United States
AVP-923
   Avanir Pharmaceuticals
      2001   Phase 3   NCT00021697   United States
Azilect® 1 MG tabletten
   Universitätsklinikum Ulm
      2013   Phase 2   EUCTR2011-004482-32-DE   Germany
Baclofen
   AZIENDA OSPEDALIERO-UNIVERSITARIA
      2010   -   EUCTR2010-020257-13-IT   Italy
Baricitinib
   Massachusetts General Hospital
      2022   Phase 1/Phase 2   NCT05189106   United States
Barium
   Milton S. Hershey Medical Center
      2022   -   NCT04889898   United States
Basiliximab
   Emory University
      2013   Phase 2   NCT01884571   United States
Betamethasone sodium phosphate/betamethasone acetate (celestone® soluspan®), 30 MG IM once A DAY FOR four days
   Edward Kasaraskis
      2017   Early Phase 1   NCT03707795   United States
BHV-0223
   Biohaven Pharmaceuticals, Inc.
      2018   Phase 1   NCT03520517   United States
BIIB050 / KNS-760704
   Biogen Idec Limited
      2011   -   EUCTR2010-022818-19-SE   Australia;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States
      2011   -   EUCTR2010-022818-19-NL   Australia;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States
      2011   -   EUCTR2010-022818-19-IE   Australia;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States
      2011   -   EUCTR2010-022818-19-GB   Australia;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States
      2011   Phase 3   EUCTR2010-022818-19-ES   Belgium;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom
      2011   -   EUCTR2010-022818-19-DE   Australia;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States
      2011   Phase 3   EUCTR2010-022818-19-BE   Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States
   Biogen Idec Research Limited
      2012   -   EUCTR2011-006119-70-SE   Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States
      2012   -   EUCTR2011-006119-70-NL   Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States
      2012   -   EUCTR2011-006119-70-IE   Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States
      2012   -   EUCTR2011-006119-70-GB   Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States
      2012   -   EUCTR2011-006119-70-ES   Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States
      2012   -   EUCTR2011-006119-70-DE   Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States
      2012   Phase 3   EUCTR2011-006119-70-BE   Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States
BIIB050/KNS-760704
   Biogen Idec Research Limited
      2012   -   EUCTR2011-006119-70-SE   Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States
      2012   -   EUCTR2011-006119-70-NL   Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States
      2012   -   EUCTR2011-006119-70-IE   Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States
      2012   -   EUCTR2011-006119-70-GB   Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States
      2012   -   EUCTR2011-006119-70-ES   Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States
      2012   -   EUCTR2011-006119-70-DE   Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States
      2012   Phase 3   EUCTR2011-006119-70-BE   Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States
BIIB067
   BIOGEN IDEC RESEARCH LIMITED
      2022   Phase 3   EUCTR2020-004590-51-IT   Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2016-003225-41-IT   Australia;Belgium;Canada;Denmark;European Union;Germany;Italy;Japan;Poland;Spain;United Kingdom;United States
   Biogen Idec Research Limited
      2021   Phase 3   EUCTR2020-004590-51-FR   Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004590-51-ES   Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
      2021   Phase 3   EUCTR2016-003225-41-ES   Australia;Belgium;Canada;Denmark;European Union;Germany;Israel;Italy;Japan;New Zealand;Poland;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2016-003225-41-DK   Australia;Belgium;Canada;Denmark;European Union;Germany;Israel;Italy;Japan;New Zealand;Poland;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2015-004098-33-PL   Argentina;Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Poland;Sweden;United Kingdom;United States
      2020   Phase 1;Phase 2;Phase 3   EUCTR2015-004098-33-DK   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Poland;Sweden;United Kingdom;United States
      2018   Phase 3   EUCTR2016-003225-41-DE   Australia;Belgium;Canada;Denmark;European Union;Germany;Israel;Italy;Japan;New Zealand;Poland;Spain;United Kingdom;United States
      2017   Phase 1;Phase 3   EUCTR2016-003225-41-GB   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Poland;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2016-003225-41-BE   Australia;Belgium;Canada;Denmark;European Union;Germany;Israel;Italy;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States
      2016   Phase 1;Phase 2;Phase 3   EUCTR2015-004098-33-SE   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Sweden;United Kingdom;United States
      2016   Phase 1;Phase 2;Phase 3   EUCTR2015-004098-33-GB   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Sweden;United Kingdom;United States
      2016   Phase 1;Phase 2;Phase 3   EUCTR2015-004098-33-DE   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Poland;Sweden;United Kingdom;United States
      2016   Phase 1;Phase 2;Phase 3   EUCTR2015-004098-33-BE   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Poland;Sweden;United Kingdom;United States
      -   Phase 3   EUCTR2015-004098-33-IT   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Poland;Sweden;United Kingdom;United States
   Cho Kyo
      2024   -   JPRN-jRCT2071240022   -
BIIB067 (ISIS666853)
   Biogen Idec Research Limited
      2020   Phase 3   EUCTR2016-003225-41-PL   Argentina;Australia;Belgium;Canada;Denmark;European Union;Germany;Italy;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States
BIIB067, qalsody
   Biogen Idec Research Limited
      2021   Phase 3   EUCTR2020-004590-51-DE   Australia;Belgium;Brazil;Canada;France;Germany;Italy;Japan;Korea, Republic of;Poland;Spain;Sweden;United Kingdom;United States
BIIB078
   Biogen
      2020   Phase 1   NCT04288856   Canada;Netherlands;Switzerland;United Kingdom;United States
      2018   Phase 1   NCT03626012   Canada;Ireland;Netherlands;Switzerland;United Kingdom;United States
BIIB100
   Biogen
      2019   Phase 1   NCT03945279   United States
BIIB105
   Biogen
      2020   Phase 1/Phase 2   NCT04494256   Canada;Italy;Netherlands;United States
Biotin
   American University of Beirut Medical Center
      2018   Phase 2   NCT03427086   Lebanon
   MEDDAY PHARMACEUTICALS
      2016   Phase 2   EUCTR2015-005810-31-FR   France
Blood sample
   University Hospital, Tours
      2024   -   NCT06230562   -
Blood sample and environmental survey
   Centre Hospitalier Universitaire de Pointe-a-Pitre
      2014   -   NCT03367650   Guadeloupe;Martinique
BLZ945
   Novartis Pharma AG
      2019   Phase 2   EUCTR2019-000826-22-SE   Australia;Finland;Sweden;United States
      2019   Phase 2   EUCTR2019-000826-22-FI   Australia;Finland;Sweden;United States
   Novartis Pharmaceuticals
      2019   Phase 2   NCT04066244   Australia;Finland;Sweden;United States
Bone marrow aspiration
   Brainstorm-Cell Therapeutics
      2017   Phase 3   NCT03280056   United States
Bosutinib
   Center for iPS Cell Research and Application (CiRA), Kyoto University
      2019   Phase 1   JPRN-jRCT1090220419   Japan
   Center for iPS Cell Research and Application, Kyoto University
      2019   Phase 1   JPRN-UMIN000036295   Japan
   Inoue Haruhisa
      2022   Phase 2   JPRN-jRCT2051220002   -
      2019   Phase 1   JPRN-jRCT2051190001   -
   Kyoto University
      2019   Phase 1/Phase 2   NCT04744532   Japan
Botox injection
   Hospices Civils de Lyon
      2012   Phase 2   NCT01551940   France
Botulinum toxin type A
   Hospices Civils de Lyon
      2011   Phase 2   EUCTR2010-023161-21-FR   France
Botulinum toxin type B
   The University of Texas Health Science Center at San Antonio
      2003   Phase 2/Phase 3   NCT00125203   United States
BRX-345
   ORPHAZYME APS
      2019   Phase 3   EUCTR2019-000374-39-IT   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2018   Phase 3   EUCTR2018-000137-13-IT   Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
   Orphazyme A/S
      2019   Phase 3   EUCTR2019-000374-39-SE   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2019-000374-39-PL   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2019-000374-39-NL   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2019-000374-39-GB   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2019-000374-39-ES   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2019-000374-39-DE   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2018   Phase 3   EUCTR2018-000137-13-SE   Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2018   Phase 3   EUCTR2018-000137-13-PL   Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2018   Phase 3   EUCTR2018-000137-13-NL   Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2018   Phase 3   EUCTR2018-000137-13-GB   Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2018   Phase 3   EUCTR2018-000137-13-FR   Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2018   Phase 3   EUCTR2018-000137-13-ES   Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2018   Phase 3   EUCTR2018-000137-13-BE   Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
Butylphthalide
   Peking Union Medical College Hospital
      2015   -   ChiCTR-IPR-15007365   China
Caffeine
   Genentech, Inc.
      2016   Phase 1   NCT02655614   Canada;Netherlands;United States
Calogen
   University of Ulm
      2015   -   NCT02306590   Germany
Cannabis sativa extract oromucosal spray
   Ospedale San Raffaele
      2013   Phase 2/Phase 3   NCT01776970   Italy
Cannabis, medical
   OMNI Medical Services, LLC
      2018   Phase 2   NCT03944447   United States
Capsaicin
   University of Florida
      2016   Early Phase 1   NCT02710162   United States
      2016   Early Phase 1   NCT02710110   United States
Capsaicin challenge
   University of Florida
      2017   -   NCT02962050   United States
Carbolithium
   I.N.M. NEUROMED (I.R.C.C.S.) S.R.L. GIA' SANATRIX
      2007   -   EUCTR2007-002379-16-IT   Italy
   ISTITUTO SUPERIORE DI SANITA`
      2009   -   EUCTR2008-006722-34-IT   Italy
Carbolithium*100CPS 150MG
   AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO
      2008   -   EUCTR2008-001094-15-IT   Italy
Carbonate DE lithium
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2008   -   EUCTR2008-003707-32-FR   France
CC100
   Chemigen, LLC
      2017   Phase 1   NCT03049046   United States
Ceftriaxone
   AZIENDA OSPEDALIERA PISANA
      2007   -   EUCTR2007-004165-17-IT   Italy
   Massachusetts General Hospital
      2006   Phase 3   NCT00349622   Canada;Puerto Rico;United States
Celebrex, celcox
   NeuroSense Therapeutics Ltd
      2022   Phase 2   EUCTR2022-002185-32-IT   Israel;Italy;United States
Celecoxib
   Columbia University
      2006   Phase 2   NCT00355576   United States
   NeuroSense Therapeutics Ltd
      2022   Phase 2   EUCTR2022-002185-32-IT   Israel;Italy;United States
   Southern Medical University Southern Hospital
      2025   -   ChiCTR2500095560   China
CELL-based therapeutics
   Pomeranian Medical University Szczecin
      2010   Phase 1   NCT02193893   Poland
CELL-based therapy
   University of Warmia and Mazury
      2015   Phase 1   NCT02881489   -
      2015   Phase 1   NCT02881476   -
CELL-based therapy OF autologous adipose derived regenerative cells transplanted intraspinally and intrathecally IN ALS patients
   Mossakowski Medical Research Centre Polish Academy of Sciences
      2015   Phase 1   NCT03296501   Poland
Censavudine
   Transposon Therapeutics, Inc
      2022   Phase 2   EUCTR2021-002251-11-FR   Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-002251-11-ES   Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-002251-11-BE   Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States
      2021   Phase 2   EUCTR2021-002251-11-DE   Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States
Cimetidine plus dexpramipexole
   Knopp Biosciences
      2012   Phase 1   NCT01536249   United States
Cipro, ciprofloxacin
   NeuroSense Therapeutics Ltd
      2022   Phase 2   EUCTR2022-002185-32-IT   Israel;Italy;United States
Ciprofloxacin
   Southern Medical University Southern Hospital
      2025   -   ChiCTR2500095560   China
Ciprofloxacina cloridrato
   NeuroSense Therapeutics Ltd
      2022   Phase 2   EUCTR2022-002185-32-IT   Israel;Italy;United States
Cistanche total glycosides
   Peking University
      2008   Phase 2   NCT00753571   China
CK-2017357
   CYTOKINETICS, INC.
      2017   Phase 3   EUCTR2016-002629-13-IT   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2014-005413-23-IT   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States
   Cytokinetics
      2012   Phase 2   NCT01709149   Canada;France;Germany;Ireland;Netherlands;Spain;United Kingdom;United States
      2011   Phase 2   NCT01486849   United States
      2011   Phase 2   NCT01378676   United States
   Cytokinetics Inc
      2013   -   EUCTR2012-004987-23-IE   Canada;Germany;Ireland;Netherlands;Spain;United Kingdom;United States
      2013   Phase 2   EUCTR2012-004987-23-GB   Canada;Germany;Ireland;Netherlands;Spain;United Kingdom;United States
      2013   Phase 2   EUCTR2012-004987-23-ES   Canada;France;Germany;Ireland;Netherlands;Spain;United Kingdom;United States
      2013   -   EUCTR2012-004987-23-DE   Canada;Germany;Ireland;Netherlands;Spain;United Kingdom;United States
      -   -   EUCTR2012-004987-23-NL   Canada;France;Germany;Ireland;Netherlands;Spain;United Kingdom;United States
   Cytokinetics, Inc.
      2017   Phase 3   EUCTR2016-002629-13-PT   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002629-13-NL   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002629-13-IE   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002629-13-GB   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002629-13-FR   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002629-13-ES   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002629-13-BE   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2014-005413-23-PT   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2014-005413-23-NL   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2014-005413-23-IE   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2014-005413-23-ES   Belgium;Canada;France;Germany;Ireland;Netherlands;Portugal;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2014-005413-23-DE   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2014-005413-23-BE   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States
      2015   Phase 3   EUCTR2014-005413-23-GB   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States
CK-2127107
   CYTOKINETICS, INC.
      2023   Phase 3   EUCTR2021-004727-33-IT   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004040-29-IT   Australia;Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
   Cytokinetics Inc
      2023   Phase 3   EUCTR2021-004727-33-PT   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
      2023   Phase 3   EUCTR2021-004727-33-NL   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
      2023   Phase 3   EUCTR2021-004727-33-DK   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
      2023   Phase 3   EUCTR2021-004727-33-BE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2020-004040-29-PT   Australia;Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2020-004040-29-PL   Australia;Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004040-29-SE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004040-29-NL   Australia;Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004040-29-IE   Australia;Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004040-29-FR   Australia;Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004040-29-ES   Australia;Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004040-29-BE   Australia;Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
      -   Phase 3   EUCTR2021-004727-33-SE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
      -   Phase 3   EUCTR2020-004040-29-DE   Australia;Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
   Cytokinetics, Inc.
      2018   Phase 2   EUCTR2018-000586-37-NL   Australia;Canada;Ireland;Netherlands;Spain;United States
      2018   Phase 2   EUCTR2018-000586-37-IE   Australia;Canada;Ireland;Netherlands;Spain;United States
      2018   Phase 2   EUCTR2018-000586-37-ES   Australia;Canada;Ireland;Netherlands;Spain;United States
CK0803
   Cellenkos, Inc.
      2023   Phase 1   NCT05695521   United States
CK2017357
   Cytokinetics Inc
      2013   -   EUCTR2012-004987-23-IE   Canada;Germany;Ireland;Netherlands;Spain;United Kingdom;United States
      2013   Phase 2   EUCTR2012-004987-23-GB   Canada;Germany;Ireland;Netherlands;Spain;United Kingdom;United States
      2013   Phase 2   EUCTR2012-004987-23-ES   Canada;France;Germany;Ireland;Netherlands;Spain;United Kingdom;United States
      2013   -   EUCTR2012-004987-23-DE   Canada;Germany;Ireland;Netherlands;Spain;United Kingdom;United States
      -   -   EUCTR2012-004987-23-NL   Canada;France;Germany;Ireland;Netherlands;Spain;United Kingdom;United States
Clenbuterol
   Dwight Koeberl, M.D., Ph.D.
      2020   Phase 2   NCT04245709   United States
CNM-AU8
   Clene Nanomedicine
      2025   -   NCT06408727   United States
      2022   -   NCT05281484   United States
      2019   Phase 2   NCT04098406   Australia
Cnmau8
   Clene Nanomedicine
      2021   Phase 2   NCT05299658   Australia
CNS10-NPC-gdnf
   Cedars-Sinai Medical Center
      2022   Phase 1   NCT05306457   United States
Coenzyme Q10
   Columbia University
      2005   Phase 2   NCT00243932   United States
Colchicina lirca - 1 MG compresse 60 compresse
   AZIENDA OSPEDALIERO-UNIVERSITARIA POLICLINICO DI MODENA
      2018   Phase 2   EUCTR2017-004459-21-IT   Italy
Colchicine 1 MG oral tablet
   Azienda Ospedaliero-Universitaria di Modena
      2019   Phase 2   NCT03693781   Italy
Communicative effectiveness survey
   University of Florida
      2016   Early Phase 1   NCT02710162   United States
Copegus
   Apodemus AB
      2014   Phase 2   EUCTR2012-002099-15-SE   Sweden
CORT113176
   Corcept Therapeutics Incorporated
      2022   Phase 2   EUCTR2021-005611-31-PL   Belgium;Canada;France;Germany;Ireland;Netherlands;Poland;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-005611-31-NL   Belgium;Canada;France;Germany;Ireland;Netherlands;Poland;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-005611-31-FR   Belgium;Canada;France;Germany;Ireland;Netherlands;Poland;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-005611-31-DE   Belgium;Canada;France;Germany;Ireland;Netherlands;Poland;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-005611-31-BE   Belgium;Canada;France;Germany;Ireland;Netherlands;Poland;Spain;United Kingdom;United States
Creatine
   Columbia University
      2006   Phase 2   NCT00355576   United States
   National Center for Research Resources (NCRR)
      2000   Phase 2   NCT00005674   United States
   Nazem Atassi
      2011   Phase 2   NCT01257581   United States
Creatine monohydrate
   National Center for Complementary and Integrative Health (NCCIH)
      2002   Phase 2   NCT00070993   United States
   The Avicena Group
      2003   Phase 3   NCT00069186   United States
Creatinine
   National Center for Research Resources (NCRR)
      2000   Phase 2   NCT00005766   United States
Crizotinib
   Yichang Central People's Hospital
      2024   Phase 2   ChiCTR2400092197   China
Cromolyn
   AZTherapies, Inc.
      2020   Phase 2   NCT04428775   United States
CU(II)atsm
   Collaborative Medicinal Development Pty Limited
      2020   Phase 2   NCT04313166   Australia
      2019   Phase 2/Phase 3   NCT04082832   Australia
      2018   Phase 1/Phase 2   NCT03136809   Australia
      2016   Phase 1   NCT02870634   Australia
Cycloserine
   West China Hospital, Sichuan University
      2025   -   ChiCTR2500097631   China
Células madre mesenquimales DE tejido adiposo AUTólogo
   FUNDACIÓN PROGRESO Y SALUD
      2013   -   EUCTR2011-006254-85-ES   Spain
Células mesenquimales DE tejido adiposo
   FUNDACIÓN PROGRESO Y SALUD
      2013   -   EUCTR2011-006254-85-ES   Spain
Células troncales hematopoyéticas AUTólogas adultas extraidas DE Médula óSEA
   Fundación Sanitaria para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO)
      2014   -   EUCTR2011-004801-25-ES   Spain
Daraprim
   Weill Medical College of Cornell University
      2013   -   EUCTR2011-004798-99-DE   Germany;Italy;United States
Darifenacin 7.5 MG extended release oral tablet
   McGill University
      2024   Phase 2   NCT06249867   Canada
Darunavir
   National Institute of Neurological Disorders and Stroke (NINDS)
      2019   Phase 1   NCT02437110   United States
Datscan
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2010   -   EUCTR2008-003982-21-FR   France
   Assistance Publique - Hôpitaux de Paris
      2012   Phase 3   NCT01160263   France
Dazucorilant
   Corcept Therapeutics Incorporated
      2022   Phase 2   EUCTR2021-005611-31-PL   Belgium;Canada;France;Germany;Ireland;Netherlands;Poland;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-005611-31-NL   Belgium;Canada;France;Germany;Ireland;Netherlands;Poland;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-005611-31-FR   Belgium;Canada;France;Germany;Ireland;Netherlands;Poland;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-005611-31-DE   Belgium;Canada;France;Germany;Ireland;Netherlands;Poland;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-005611-31-BE   Belgium;Canada;France;Germany;Ireland;Netherlands;Poland;Spain;United Kingdom;United States
Dazucorilant 150 MG
   Corcept Therapeutics
      2022   Phase 2   NCT05407324   Belgium;Canada;France;Germany;Ireland;Netherlands;Poland;Spain;United Kingdom;United States
Dazucorilant 300 MG
   Corcept Therapeutics
      2022   Phase 2   NCT05407324   Belgium;Canada;France;Germany;Ireland;Netherlands;Poland;Spain;United Kingdom;United States
Debamestrocel
   Brainstorm-Cell Therapeutics
      2025   Phase 3   NCT06973629   United States
Deferiprone
   University Hospital, Lille
      2019   Phase 2/Phase 3   NCT03293069   France
      2013   Phase 2   NCT02164253   France
      2011   -   NCT02880033   France
Deferiprone DR
   centre hospitalier universitaire de Lille
      2018   Phase 3   EUCTR2017-003763-35-FR   France
Dexdor
   Turku University Hospital
      2018   Phase 4   EUCTR2018-000142-18-FI   Finland
Dexmedetomidine
   Turku University Hospital
      2018   Phase 4   EUCTR2018-000142-18-FI   Finland
Dexpramipexole
   Biogen Idec Limited
      2011   Phase 3   EUCTR2010-022818-19-ES   Belgium;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom
   Biogen Idec Research Limited
      2012   -   EUCTR2011-006119-70-SE   Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States
      2012   -   EUCTR2011-006119-70-NL   Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States
      2012   -   EUCTR2011-006119-70-IE   Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States
      2012   -   EUCTR2011-006119-70-GB   Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States
      2012   -   EUCTR2011-006119-70-ES   Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States
      2012   -   EUCTR2011-006119-70-DE   Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States
      2012   Phase 3   EUCTR2011-006119-70-BE   Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States
   Knopp Biosciences
      2012   Phase 3   NCT01622088   Australia;Belgium;Canada;France;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States
      2012   Phase 1   NCT01511029   United States
      2011   Phase 1   NCT01449578   United States
      2011   Phase 1   NCT01424176   United States
      2011   Phase 3   NCT01281189   Australia;Belgium;Canada;France;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States
Dexpramipexole dichydrochloride
   Biogen Idec Limited
      2011   -   EUCTR2010-022818-19-SE   Australia;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States
      2011   -   EUCTR2010-022818-19-NL   Australia;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States
      2011   -   EUCTR2010-022818-19-IE   Australia;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States
      2011   -   EUCTR2010-022818-19-GB   Australia;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States
      2011   Phase 3   EUCTR2010-022818-19-BE   Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States
Dexpramipexole dihydrochloride
   Biogen Idec Limited
      2011   -   EUCTR2010-022818-19-DE   Australia;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States
Dextran
   University of Birmingham
      2018   Phase 2   EUCTR2018-000668-28-GB   United Kingdom
Dextran sulfate sodium
   TikoMed AB
      2018   Phase 2   EUCTR2017-005065-47-SE   Sweden
Dextromethorphan HBR and quinidine sulfate
   University of Florida
      2019   Phase 1/Phase 2   NCT03883581   United States
Dextromethorphan hydrobromide 20 MG and quinidine sulfate 10 MG
   Avanir Pharmaceuticals
      2007   Phase 3   NCT00573443   Argentina;Brazil;United States
Dextromethorphan hydrobromide 30 MG and quinidine sulfate 10 MG
   Avanir Pharmaceuticals
      2007   Phase 3   NCT00573443   Argentina;Brazil;United States
Digital recording OF speech and swallow sounds using THE beiwe digital health APP ON A personal smartphone
   Milton S. Hershey Medical Center
      2022   -   NCT04889898   United States
Diluent
   Regeneron Pharmaceuticals
      2024   Phase 1   NCT06351592   Canada;Japan;Korea, Republic of
DNL343
   Denali Therapeutics Inc.
      2021   Phase 1   NCT05006352   Netherlands;United States
   Merit E. Cudkowicz, MD
      2023   Phase 2/Phase 3   NCT05842941   United States
      2020   Phase 2/Phase 3   NCT04297683   United States
DNL747
   Sanofi
      2018   Phase 1   NCT03757351   Netherlands;United States
Dolutegravir
   Macquarie University, Australia
      2024   Phase 3   NCT06658977   Australia
   National Institute of Neurological Disorders and Stroke (NINDS)
      2019   Phase 1   NCT02437110   United States
   Stichting TRICALS Foundation
      2023   Phase 3   EUCTR2020-005069-15-SI   Australia;Ireland;Netherlands;Slovenia;Spain;United Kingdom
      2022   Phase 3   EUCTR2020-005069-15-IE   Australia;Ireland;Netherlands;Slovenia;Spain;United Kingdom
      2021   Phase 3   EUCTR2020-005069-15-NL   Australia;Ireland;Netherlands;Slovenia;Spain;United Kingdom
Dolutegravir, abacavir and lamivudine
   Macquarie University, Australia
      2022   Phase 3   NCT05193994   Australia;Ireland;Netherlands;New Zealand;Slovenia;Spain;Sweden;United Kingdom
DPA
   University Hospital, Tours
      2015   Early Phase 1   NCT02405403   France
Dronabinol
   Cantonal Hospital of St. Gallen
      2005   -   NCT00812851   Switzerland
Dutasterida
   Facultad de medicina y ciencias de la salud de la Universidad Católica de Valencia
      2021   Phase 2   EUCTR2021-001989-38-ES   Spain
Dutasteride
   Facultad de medicina y ciencias de la salud de la Universidad Católica de Valencia
      2021   Phase 2   EUCTR2021-001989-38-ES   Spain
Eating assessment tool 10
   University of Florida
      2017   -   NCT02962050   United States
Eating assessment TOOL-10
   University of Florida
      2016   Early Phase 1   NCT02710162   United States
Ebixa
   Jorge Matias-Guiu Guia
      2008   -   EUCTR2007-002117-39-ES   Spain
   University of Lisbon
      2005   Phase 2/Phase 3   NCT00353665   Portugal
Edaravone
   Ehime University Hospital
      2015   Phase 1,2   JPRN-UMIN000016352   Japan
   Ferrer Internacional S.A.
      2023   Phase 3   EUCTR2022-003050-32-IT   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom
      2021   Phase 3   EUCTR2020-003376-40-IT   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom
   Ferrer Internacional, S.A.
      2023   Phase 3   EUCTR2022-003050-32-SE   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom
      2023   Phase 3   EUCTR2022-003050-32-PT   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom
      2023   Phase 3   EUCTR2022-003050-32-PL   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom
      2023   Phase 3   EUCTR2022-003050-32-DE   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom
      2023   Phase 3   EUCTR2022-003050-32-BE   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom
      2022   Phase 3   EUCTR2020-003376-40-SE   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom
      2022   Phase 3   EUCTR2020-003376-40-PT   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom
      2021   Phase 3   EUCTR2020-003376-40-PL   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom
      2021   Phase 3   EUCTR2020-003376-40-NL   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom
      2021   Phase 3   EUCTR2020-003376-40-IE   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom
      2021   Phase 3   EUCTR2020-003376-40-ES   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Russian Federation;Spain;United Kingdom
      2021   Phase 3   EUCTR2020-003376-40-DE   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom
      2021   Phase 3   EUCTR2020-003376-40-BE   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom
   Isfahan University of Medical Sciences
      2017   Phase 2/Phase 3   NCT03272802   Iran, Islamic Republic of
   Kazuoki Kondo
      2022   Phase 3   JPRN-jRCT2041220069   -
   Kondo Kazuoki
      2022   Phase 3   JPRN-jRCT2071210117   Canada;Germany;Italia;Japan;South Korea;Switzerland;US
      2021   Phase 1   JPRN-jRCT2031200361   -
      2021   Phase 3   JPRN-jRCT2031200301   Canada;France;Germany;Italy;Japan;Korea;Switzerland;United States of America
      2020   Phase 3   JPRN-jRCT2041200084   Canada;France;Germany;Italy;Japan;United States of America
   Mitsubishi Tanabe Development America Inc.
      2021   Phase 3   EUCTR2020-000376-38-IT   Canada;France;Germany;Italy;Japan;United States
      2021   Phase 3   EUCTR2019-004256-11-IT   Canada;France;Germany;Italy;Japan;Korea, Republic of;Switzerland;United States
      2020   Phase 3   EUCTR2019-002108-41-IT   Canada;France;Germany;Italy;Japan;United States
   Mitsubishi Tanabe Pharma America Inc.
      2019   -   NCT04259255   Canada;United States
   Mitsubishi Tanabe Pharma America, Inc. (MTPA)
      2022   Phase 3   EUCTR2021-003900-42-DE   Canada;Germany;Italy;Japan;Korea, Republic of;Switzerland;United States
   Mitsubishi Tanabe Pharma Corporation
      2020   Phase 1   JPRN-jRCT2080225036   Japan
      2019   Phase 1   JPRN-jRCT2080224962   Japan
   Mitsubishi Tanabe Pharma Development America, Inc.
      2021   Phase 3   EUCTR2020-000376-38-FR   Canada;France;Germany;Italy;Japan;United States
      2021   Phase 3   EUCTR2020-000376-38-DE   Canada;France;Germany;Italy;Japan;United States
      2020   Phase 3   EUCTR2019-002108-41-DE   Canada;France;Germany;Italy;Japan;United States
   Mitsubishi Tanabe Pharma Development America, Inc. (MTDA)
      2021   Phase 3   EUCTR2019-004256-11-DE   Canada;Germany;Italy;Japan;Korea, Republic of;Switzerland;United States
   Okayama university
      2016   -   JPRN-UMIN000024854   Japan
   Yichang Central People's Hospital
      2025   Phase 4   ChiCTR2500099139   China
      2024   Phase 4   ChiCTR2400082879   China
Electrical impedance myography
   University of Florida
      2016   Early Phase 1   NCT02710162   United States
Engensis
   Helixmith Co., Ltd.
      2021   Phase 2   NCT05176093   Korea, Republic of;United States
      2021   Phase 2   NCT04632225   Korea, Republic of;United States
Enoxacin
   McGill University
      2021   Phase 1/Phase 2   NCT04840823   Canada
Eperisone
   AZIENDA OSPEDALIERO-UNIVERSITARIA
      2010   -   EUCTR2010-020257-13-IT   Italy
EPI-589
   Fujita Koji
      2021   Phase 2   JPRN-jRCT2061210031   -
   Hamatani Tatsuto
      2022   Phase 1   JPRN-jRCT2071220047   -
      2021   Phase 1   JPRN-jRCT2071210023   -
      2018   Phase 1   JPRN-jRCT2071210022   -
   Nagano Seiichi
      2023   -   JPRN-jRCTs051230064   -
   PTC Therapeutics
      2016   Phase 2   NCT02460679   United States
Eprex IV SC 1FL 1ML 40000 UI
   ISTITUTO NEUROLOGICO CARLO BESTA
      2005   -   EUCTR2005-005873-31-IT   Italy
Eprex*1SIR 40000UI/ML 1ML
   ISTITUTO NEUROLOGICO CARLO BESTA
      2011   -   EUCTR2011-001329-26-IT   Italy
      2010   -   EUCTR2009-016066-91-IT   Italy
Erythromycin ethyl succinate
   Sanofi
      2022   Phase 1   NCT05797753   United States
Erythropoietin
   Hanyang University Seoul Hospital
      2016   Phase 1/Phase 2   NCT03835507   Korea, Republic of
   ISTITUTO NEUROLOGICO CARLO BESTA
      2005   -   EUCTR2005-005873-31-IT   Italy
   ISTITUTO NEUROLOGICO CARLO BESTA
      2011   -   EUCTR2011-001329-26-IT   Italy
      2010   -   EUCTR2009-016066-91-IT   Italy
Escitalopram
   University of South Carolina
      2009   Phase 3   NCT00965497   United States
Esketamine
   Turku University Hospital
      2018   Phase 4   EUCTR2018-000142-18-FI   Finland
Excipient
   Cellenkos, Inc.
      2023   Phase 1   NCT05695521   United States
Exosomes derived from human umbilical cord blood mesenchymal stem cells FOR nasal drop
   Xuanwu Hospital, Beijing
      2024   Phase 1/Phase 2   NCT06598202   China
Ezogabine
   Brian Wainger
      2015   Phase 2   NCT02450552   United States
F 18 T807
   Tammie L. S. Benzinger, MD, PhD
      2015   -   NCT02414230   United States
FAB122
   Ferrer Internacional S.A.
      2023   Phase 3   NCT05866926   Spain
      2023   Phase 3   EUCTR2022-003050-32-IT   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom
      2021   Phase 3   NCT05178810   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2021   Phase 3   EUCTR2020-003376-40-IT   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom
   Ferrer Internacional, S.A.
      2023   Phase 3   EUCTR2022-003050-32-SE   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom
      2023   Phase 3   EUCTR2022-003050-32-PT   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom
      2023   Phase 3   EUCTR2022-003050-32-PL   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom
      2023   Phase 3   EUCTR2022-003050-32-DE   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom
      2023   Phase 3   EUCTR2022-003050-32-BE   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom
      2022   Phase 3   EUCTR2020-003376-40-SE   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom
      2022   Phase 3   EUCTR2020-003376-40-PT   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom
      2021   Phase 3   EUCTR2020-003376-40-PL   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom
      2021   Phase 3   EUCTR2020-003376-40-NL   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom
      2021   Phase 3   EUCTR2020-003376-40-IE   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom
      2021   Phase 3   EUCTR2020-003376-40-ES   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Russian Federation;Spain;United Kingdom
      2021   Phase 3   EUCTR2020-003376-40-DE   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom
      2021   Phase 3   EUCTR2020-003376-40-BE   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom
FAMC-1
   Polski Bank Komórek Macierzystych JSC (PBKM)
      2020   Phase 1;Phase 2   EUCTR2018-004171-12-PL   Poland
Fasudil
   Peking University Third Hospital
      2013   Phase 2   NCT01935518   China
   University Medical Center Goettingen
      2019   Phase 2   NCT03792490   France;Germany;Switzerland
   Woolsey Pharmaceuticals
      2021   Phase 2   NCT05218668   Australia;United States
Fasudil hydrochloride
   Georg-August-Universität Göttingen
      2019   Phase 2   EUCTR2017-003676-31-FR   France;Germany;Switzerland
FB1006
   Peking University Third Hospital
      2023   Phase 4   NCT05923905   China
FB418
   1ST Biotherapeutics, Inc.
      2023   Phase 1   NCT05995782   Korea, Republic of
Febuxostat
   Teikyo University
      2017   -   JPRN-UMIN000029308   Japan
   Tsukuba International Clinical Pharmacology Clinic
      2016   -   JPRN-UMIN000024312   Japan
Fecal microbiota transplantation
   Azienda Ospedaliero-Universitaria di Modena
      2020   -   NCT03766321   Italy
Fenilbutirato
   Amylyx Pharmaceuticals Inc.
      2021   Phase 3   EUCTR2021-000250-26-ES   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
FIG
   FeGALS
      2009   -   JPRN-UMIN000008527   Japan
Filgrastim
   MinYoung Kim, M.D.
      2014   -   NCT02236065   Korea, Republic of
   Università degli Studi di Torino e Azienda Ospedaliera Città della Salute e della Scienza di Torino
      2014   Phase 2   EUCTR2014-002228-28-IT   Italy
Fixed dose combination ciprofloxacin/celecoxib
   NeuroSense Therapeutics Ltd.
      2019   Phase 2   NCT04165850   Israel
      2019   Phase 1   NCT04090684   United States
FLX-787-ODT
   Flex Pharma, Inc.
      2018   Phase 1/Phase 2   NCT03334786   United States
      2017   Phase 1/Phase 2   NCT03338114   United States
Fosigotifator
   AbbVie
      2021   Phase 1   NCT04948645   Canada;United States
Functional oral intake scale
   University of Florida
      2016   Early Phase 1   NCT02710162   United States
Fycompa
   American University of Beirut Medical Center
      2019   Phase 2   NCT03377309   Lebanon
G-CSF
   University Hospital Muenster
      2006   Phase 2   NCT00298597   Germany
G04cb02
   Fundación Universidad Católica de Valencia San Vicente Mártir
      2021   Phase 2   NCT04654689   Spain
GDC-0134
   Genentech, Inc.
      2016   Phase 1   NCT02655614   Canada;Netherlands;United States
Gilenya
   Massachusetts General Hospital
      2013   Phase 2   NCT01786174   United States
GM604
   Genervon Biopharmaceuticals, LLC
      2013   Phase 2   NCT01854294   United States
Gold nanocrystals
   Clene Nanomedicine
      2020   Phase 2   NCT03843710   United States
Granulocyte colony stimulating factor
   Peking University
      2006   Phase 2   NCT00397423   China
   Tehran University of Medical Sciences
      2012   Phase 2/Phase 3   NCT01825551   Iran, Islamic Republic of
Growth hormone
   Federico II University
      2007   Phase 2   NCT00635960   Italy
GSK1223249
   GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.
      2012   -   EUCTR2012-003349-13-IT   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States
   GlaxoSmithKline
      2009   Phase 1   NCT00875446   France;Italy;United Kingdom;United States
   GlaxoSmithKline Research and Development Limited
      2013   -   EUCTR2012-003349-13-NL   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States
      2013   -   EUCTR2012-003349-13-DE   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States
      2012   Phase 2   EUCTR2012-003349-13-GB   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States
      2012   Phase 2   EUCTR2012-003349-13-FR   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States
      2012   -   EUCTR2012-003349-13-BE   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States
Guana2015
   FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA
      2016   Phase 2   EUCTR2014-005367-32-IT   Italy
Guanabenz acetato
   FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA
      2016   Phase 2   EUCTR2014-005367-32-IT   Italy
HB-admscs
   Hope Biosciences Stem Cell Research Foundation
      2020   -   NCT04514952   United States
Historical control
   Richard Bedlack, M.D., Ph.D.
      2016   Phase 2   NCT02709330   United States
HK-001
   Everfront Biotech Co., Ltd.
      2021   Phase 1   NCT03651349   Taiwan
Hnsc
   FONDAZIONE CASA SOLLIEVO DELLA SOFFERENZA OPERA DI SAN PIO DA PIETRELCINA OSPEDALE IRCCS
      2024   Phase 2   EUCTR2018-002373-22-IT   Italy
Human albumin solution
   Instituto Grifols S.A.
      2014   Phase 4   EUCTR2013-004842-40-ES   Spain
Human autologous mesenchymal stem cells
   Bioinova, s.r.o.
      2012   Phase 2   EUCTR2011-000362-35-CZ   Czech Republic
Human neural stem cells
   Azienda Ospedaliera Santa Maria, Terni, Italy
      2011   Phase 1   NCT01640067   Italy
Huolingshengji granules
   Peking University Third Hospital
      2020   Phase 2/Phase 3   NCT04950933   China
HYNR-CS INJ
   Corestem, Inc.
      2011   Phase 1/Phase 2   NCT01363401   Korea, Republic of
HYNR-CS-allo
   Hanyang University Seoul Hospital
      2012   Phase 1   NCT01758510   Korea, Republic of
Hynrcs-allo INJ
   Hanyang University Seoul Hospital
      2017   Phase 1   NCT03214146   Korea, Republic of
Hyperpolarized [1-13C]pyruvate
   Christoffer Laustsen
      2020   Phase 2   EUCTR2020-000352-36-DK   Denmark
I-123
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2010   -   EUCTR2008-003982-21-FR   France
Ibudilast
   MediciNova
      2016   Phase 1/Phase 2   NCT02714036   United States
   MediciNova, Inc.
      2020   Phase 2;Phase 3   EUCTR2019-003549-14-HU   Germany;Greece;Hungary;Italy;Poland;Spain;United States
IC14
   Implicit Bioscience
      2021   Phase 2   NCT04390386   United States
      2019   -   NCT04309604   United States
      2019   Phase 2   NCT03508453   Australia
      2019   Phase 2   NCT03474263   Australia;United States
      2017   Phase 1   NCT03487263   Australia
Icerguastat
   InFlectis BioScience
      2022   Phase 2   EUCTR2021-003875-32-IT   France;Italy
      2021   Phase 2   EUCTR2021-003875-32-FR   France;Italy
IFB-088
   InFlectis BioScience
      2022   Phase 2   EUCTR2021-003875-32-IT   France;Italy
      2021   Phase 2   EUCTR2021-003875-32-FR   France;Italy
IFB-088 50MG/DAY
   InFlectis BioScience
      2022   Phase 2   NCT05508074   France;Italy
IL-2
   Centre Hospitalier Universitaire de Nimes
      2017   Phase 2   NCT03039673   France;United Kingdom
   Peking University Third Hospital
      2020   Phase 2   NCT04952155   China
ILB
   TikoMed AB
      2018   Phase 2   NCT03613571   Sweden
      2018   Phase 2   EUCTR2017-005065-47-SE   Sweden
   University of Birmingham
      2019   Phase 2   NCT03705390   United Kingdom
ILB: 100MG/ML solution FOR injection and infusion
   University of Birmingham
      2018   Phase 2   EUCTR2018-000668-28-GB   United Kingdom
Immunoglobulin G
   Annexon Biosciences
      2021   Phase 2   EUCTR2021-000325-26-FR   Canada;France;United States
Immunoglobulin G1, anti (protein nogo A) (human MUS musculus monoclonal heavy
   GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.
      2012   -   EUCTR2012-003349-13-IT   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States
Immunoglobulin G1, anti (protein nogo A) (human MUS musculus monoclonal heavy chain), disulfide with human MUS musculus monoclonal light chain, dimer
   GlaxoSmithKline Research and Development Limited
      2013   -   EUCTR2012-003349-13-NL   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States
      2013   -   EUCTR2012-003349-13-DE   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States
      2012   Phase 2   EUCTR2012-003349-13-GB   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States
      2012   Phase 2   EUCTR2012-003349-13-FR   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States
      2012   -   EUCTR2012-003349-13-BE   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States
Incobotulinum toxin A
   Beth Israel Deaconess Medical Center
      2012   Phase 2   NCT01565395   United States
Injection
   AL-S Pharma, AG
      2021   Phase 2   EUCTR2020-005971-11-SE   Belgium;Canada;Germany;Korea, Republic of;Sweden;United States
      2021   Phase 2   EUCTR2020-005971-11-DE   Belgium;Canada;Germany;Korea, Republic of;Sweden;United States
   AL-S Pharma, SA
      2023   Phase 2   EUCTR2020-005971-11-BE   Belgium;Canada;Germany;Korea, Republic of;Sweden;United States
   APELLIS PHARMACEUTCIALS, INC.
      2021   Phase 2   EUCTR2019-003797-10-IT   Argentina;Australia;Belgium;Brazil;Czech Republic;Czechia;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2010   -   EUCTR2008-003982-21-FR   France
   AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO
      2005   -   EUCTR2005-003248-75-IT   Italy
   Annexon Biosciences
      2021   Phase 2   EUCTR2021-000325-26-FR   Canada;France;United States
   Apellis Pharmaceuticals, Inc.
      2021   Phase 2   EUCTR2019-003797-10-NL   Argentina;Australia;Belgium;Brazil;Czech Republic;Czechia;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States
      2021   Phase 2   EUCTR2019-003797-10-IE   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Czechia;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States
      2021   Phase 2   EUCTR2019-003797-10-DE   Argentina;Australia;Belgium;Brazil;Czech Republic;Czechia;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States
      2021   Phase 2   EUCTR2019-003797-10-CZ   Argentina;Australia;Belgium;Brazil;Czech Republic;Czechia;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States
   BIOGEN IDEC RESEARCH LIMITED
      2022   Phase 3   EUCTR2020-004590-51-IT   Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2016-003225-41-IT   Australia;Belgium;Canada;Denmark;European Union;Germany;Italy;Japan;Poland;Spain;United Kingdom;United States
   Biogen Idec Research Limited
      2021   Phase 3   EUCTR2020-004590-51-FR   Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004590-51-ES   Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004590-51-DE   Australia;Belgium;Brazil;Canada;France;Germany;Italy;Japan;Korea, Republic of;Poland;Spain;Sweden;United Kingdom;United States
      2021   Phase 3   EUCTR2016-003225-41-ES   Australia;Belgium;Canada;Denmark;European Union;Germany;Israel;Italy;Japan;New Zealand;Poland;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2016-003225-41-DK   Australia;Belgium;Canada;Denmark;European Union;Germany;Israel;Italy;Japan;New Zealand;Poland;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2015-004098-33-PL   Argentina;Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Poland;Sweden;United Kingdom;United States
      2020   Phase 1;Phase 2;Phase 3   EUCTR2015-004098-33-DK   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Poland;Sweden;United Kingdom;United States
      2018   Phase 3   EUCTR2016-003225-41-DE   Australia;Belgium;Canada;Denmark;European Union;Germany;Israel;Italy;Japan;New Zealand;Poland;Spain;United Kingdom;United States
      2017   Phase 1;Phase 3   EUCTR2016-003225-41-GB   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Poland;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2016-003225-41-BE   Australia;Belgium;Canada;Denmark;European Union;Germany;Israel;Italy;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States
      2016   Phase 1;Phase 2;Phase 3   EUCTR2015-004098-33-SE   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Sweden;United Kingdom;United States
      2016   Phase 1;Phase 2;Phase 3   EUCTR2015-004098-33-GB   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Sweden;United Kingdom;United States
      2016   Phase 1;Phase 2;Phase 3   EUCTR2015-004098-33-DE   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Poland;Sweden;United Kingdom;United States
      2016   Phase 1;Phase 2;Phase 3   EUCTR2015-004098-33-BE   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Poland;Sweden;United Kingdom;United States
      -   Phase 3   EUCTR2015-004098-33-IT   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Poland;Sweden;United Kingdom;United States
   Bioinova, s.r.o.
      2012   Phase 2   EUCTR2011-000362-35-CZ   Czech Republic
   CHU DE NIMES
      2016   Phase 2   EUCTR2015-005347-14-GB   United Kingdom
   FONDAZIONE CASA SOLLIEVO DELLA SOFFERENZA OPERA DI SAN PIO DA PIETRELCINA OSPEDALE IRCCS
      2024   Phase 2   EUCTR2018-002373-22-IT   Italy
   First Affiliated Hospital of Harbin Medical University
      2025   Phase 1   ChiCTR2500101605   China
   Fundación Sanitaria para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO)
      2014   -   EUCTR2011-004801-25-ES   Spain
   Fundación para la Formación e Investigación Sanitarias de la Región de Murcia
      2019   Phase 2   EUCTR2019-002302-46-ES   Spain
   GlaxoSmithKline Research and Development Limited
      2013   -   EUCTR2012-003349-13-NL   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States
      2013   -   EUCTR2012-003349-13-DE   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States
      2012   Phase 2   EUCTR2012-003349-13-GB   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States
      2012   Phase 2   EUCTR2012-003349-13-FR   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States
      2012   -   EUCTR2012-003349-13-BE   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States
   Hospices Civils de Lyon
      2011   Phase 2   EUCTR2010-023161-21-FR   France
   IONIS PHARMACEUTICALS, INC.
      2022   Phase 1;Phase 3   EUCTR2020-005522-28-IT   Belgium;Canada;France;Germany;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Turkey;United Kingdom;United States
   ISTITUTO NEUROLOGICO CARLO BESTA
      2011   -   EUCTR2011-001329-26-IT   Italy
   Ionis Pharmaceuticals, Inc.
      2023   Phase 1;Phase 2;Phase 3   EUCTR2020-005522-28-ES   Belgium;Brazil;Canada;France;Germany;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2022   Phase 1;Phase 2;Phase 3   EUCTR2020-005522-28-NL   Belgium;Brazil;Canada;France;Germany;Ireland;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Poland;Spain;Sweden;Turkey;United Kingdom;United States
      2021   Phase 1;Phase 2;Phase 3   EUCTR2020-005522-28-BE   Belgium;Brazil;Canada;Germany;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      -   Phase 1;Phase 2;Phase 3   EUCTR2020-005522-28-SE   Belgium;Brazil;Canada;Germany;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
      -   Phase 1;Phase 2;Phase 3   EUCTR2020-005522-28-PL   Belgium;Brazil;Canada;Germany;Ireland;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      -   Phase 1;Phase 2;Phase 3   EUCTR2020-005522-28-IE   Belgium;Brazil;Canada;Germany;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
      -   Phase 1;Phase 2;Phase 3   EUCTR2020-005522-28-DE   Belgium;Brazil;Canada;France;Germany;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
   Novabio Therapeutics
      2024   Phase 1   NCT06671236   China;United States
   Polski Bank Komórek Macierzystych JSC (PBKM)
      2020   Phase 1;Phase 2   EUCTR2018-004171-12-PL   Poland
   TEVA Pharmaceutical Industries. Ltd.
      2006   Phase 2   EUCTR2006-001688-49-GB   Belgium;Germany;Italy;United Kingdom
      2006   -   EUCTR2006-001688-49-DE   Belgium;Germany;Italy;United Kingdom
      2006   -   EUCTR2006-001688-49-BE   Belgium;Germany;Italy;United Kingdom
   The Methodist Hospital Research Institute
      2021   Phase 1   NCT06307301   United States
   TikoMed AB
      2018   Phase 2   EUCTR2017-005065-47-SE   Sweden
   Università degli Studi di Torino e Azienda Ospedaliera Città della Salute e della Scienza di Torino
      2014   Phase 2   EUCTR2014-002228-28-IT   Italy
   Wave Life Sciences UK Limited
      2023   Phase 1;Phase 2   EUCTR2022-002267-29-BE   Australia;Belgium;Canada;Ireland;Netherlands;New Zealand;United Kingdom
      2022   Phase 1;Phase 2   EUCTR2020-005193-94-SE   Australia;Belgium;Canada;Germany;Ireland;Netherlands;New Zealand;Sweden;United Kingdom;United States
      2022   Phase 1;Phase 2   EUCTR2020-005193-94-BE   Australia;Belgium;Canada;Germany;Ireland;Netherlands;New Zealand;Sweden;United Kingdom;United States
      2021   Phase 1;Phase 2   EUCTR2020-005193-94-DE   Australia;Belgium;Canada;Germany;Ireland;Netherlands;New Zealand;Sweden;United Kingdom;United States
   Yichang Central People's Hospital
      2025   Phase 4   ChiCTR2500099139   China
Injection OF salivary glands
   The University of Texas Health Science Center at San Antonio
      2003   Phase 2/Phase 3   NCT00125203   United States
Inosine
   Massachusetts General Hospital
      2017   Phase 2   NCT03168711   United States
      2015   Phase 1   NCT02288091   United States
   Teikyo University
      2017   -   JPRN-UMIN000029308   Japan
   Tsukuba International Clinical Pharmacology Clinic
      2016   -   JPRN-UMIN000024312   Japan
Insulin like growth factor, type 1
   Mayo Clinic
      2003   Phase 3   NCT00035815   Puerto Rico;United States
Interleukin-2
   Nanjing Hospital Affiliated to Nanjing University of traditional Chinese Medicine
      2019   Phase 0   ChiCTR2000035966   China
   Stanley H. Appel, MD
      2016   Phase 1   NCT03241784   United States
Intra venous injection OF stem cell
   Royan Institute
      2013   Phase 1   NCT01759797   Iran, Islamic Republic of
Intrathecal autologous stem cell
   Hospital Universitario Dr. Jose E. Gonzalez
      2012   Phase 2/Phase 3   NCT01933321   Mexico
Intrathecal injection
   Beijing Tiantan Hospital
      2023   Phase 1   NCT06181526   China
   Royan Institute
      2013   Phase 1   NCT01771640   Iran, Islamic Republic of
Intravenous administration OF 1 million OF MSC
   Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud
      2014   Phase 1/Phase 2   NCT02290886   Spain
Intravenous administration OF 2 million OF MSC
   Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud
      2014   Phase 1/Phase 2   NCT02290886   Spain
Intravenous administration OF 4 million OF MSC
   Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud
      2014   Phase 1/Phase 2   NCT02290886   Spain
Intravenous injection
   Beijing Tiantan Hospital
      2023   Phase 1   NCT06181526   China
   Yichang Central People's Hospital
      2024   Phase 4   ChiCTR2400082879   China
Intraventricular injection
   Royan Institute
      2014   Phase 1   NCT01759784   Iran, Islamic Republic of
Ioflupane 123I
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2010   -   EUCTR2008-003982-21-FR   France
ION363
   IONIS PHARMACEUTICALS, INC.
      2022   Phase 1;Phase 3   EUCTR2020-005522-28-IT   Belgium;Canada;France;Germany;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Turkey;United Kingdom;United States
   Ionis Pharmaceuticals, Inc.
      2022   Phase 1;Phase 2;Phase 3   EUCTR2020-005522-28-NL   Belgium;Brazil;Canada;France;Germany;Ireland;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Poland;Spain;Sweden;Turkey;United Kingdom;United States
      2021   Phase 3   NCT04768972   Australia;Belgium;Brazil;Canada;Germany;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
      2021   Phase 1;Phase 2;Phase 3   EUCTR2020-005522-28-BE   Belgium;Brazil;Canada;Germany;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      -   Phase 1;Phase 2;Phase 3   EUCTR2020-005522-28-SE   Belgium;Brazil;Canada;Germany;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
      -   Phase 1;Phase 2;Phase 3   EUCTR2020-005522-28-PL   Belgium;Brazil;Canada;Germany;Ireland;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      -   Phase 1;Phase 2;Phase 3   EUCTR2020-005522-28-IE   Belgium;Brazil;Canada;Germany;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
      -   Phase 1;Phase 2;Phase 3   EUCTR2020-005522-28-DE   Belgium;Brazil;Canada;France;Germany;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
ION363 sodium
   Ionis Pharmaceuticals, Inc.
      2023   Phase 1;Phase 2;Phase 3   EUCTR2020-005522-28-ES   Belgium;Brazil;Canada;France;Germany;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
Iowa oral performance instrument
   University of Florida
      2017   -   NCT02962050   United States
      2016   Early Phase 1   NCT02710162   United States
Iowa oral pressure instrument
   University of Florida
      2016   Early Phase 1   NCT02710110   United States
IPL344
   Immunity Pharma Ltd.
      2018   Phase 2   NCT03755167   Israel
      2018   Phase 1/Phase 2   NCT03652805   Israel
IPSC-MNP
   Shanghai East Hospital
      2024   -   NCT06765564   China
Isis 333611
   Isis Pharmaceuticals
      2010   Phase 1   NCT01041222   United States
Isocaloric diet
   Fundación Universidad Católica de Valencia San Vicente Mártir
      2021   Phase 2   NCT04654689   Spain
Itraconazole
   Sanofi
      2022   Phase 1   NCT05797753   United States
Jevity 1.0
   Massachusetts General Hospital
      2009   Phase 2   NCT00983983   United States
Jevity 1.5
   Massachusetts General Hospital
      2009   Phase 2   NCT00983983   United States
Ketanest-S
   Turku University Hospital
      2018   Phase 4   EUCTR2018-000142-18-FI   Finland
Ketocal
   Johns Hopkins University
      2009   Phase 3   NCT01016522   United States
KNS-760704
   Knopp Biosciences
      2009   Phase 2   NCT00931944   United States
      2008   Phase 2   NCT00647296   United States
L-arginine
   Horofumi Maruyama
      2023   Phase 2   JPRN-jRCTs061230001   -
L-carnitine injection,1000MG once daily
   ChaodongWang
      2024   Phase 4   NCT06849115   China
L-serine
   Elijah W. Stommel
      2018   Phase 2   NCT03580616   United States
   Phoenix Neurological Associates, LTD
      2013   Phase 1/Phase 2   NCT01835782   United States
Lacosamide
   Chiba University
      2017   Phase 1/Phase 2   NCT03186040   Japan
   Department of Neurology Chiba University Hospital
      2017   -   JPRN-UMIN000027476   Japan
   Kuwabara Satoshi
      2017   Phase 1-2   JPRN-jRCTs031180173   -
Lactose
   FeGALS
      2009   -   JPRN-UMIN000008527   Japan
   University of Calgary
      2015   Phase 2   NCT02463825   Canada
LAM-002A
   OrphAI Therapeutics
      2021   Phase 2   NCT05163886   United States
Lamivudine
   Macquarie University, Australia
      2024   Phase 3   NCT06658977   Australia
   Stichting TRICALS Foundation
      2023   Phase 3   EUCTR2020-005069-15-SI   Australia;Ireland;Netherlands;Slovenia;Spain;United Kingdom
      2022   Phase 3   EUCTR2020-005069-15-IE   Australia;Ireland;Netherlands;Slovenia;Spain;United Kingdom
      2021   Phase 3   EUCTR2020-005069-15-NL   Australia;Ireland;Netherlands;Slovenia;Spain;United Kingdom
Lenograstim
   AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO
      2005   -   EUCTR2005-003248-75-IT   Italy
Lenzumestrocel
   Corestemchemon, Inc.
      2022   Phase 1   NCT06676423   Korea, Republic of
      2021   Phase 3   NCT04745299   Korea, Republic of
Leuprolide
   National Center for Research Resources (NCRR)
      1992   Phase 2   NCT00004771   -
Levetiracetam
   Duke University
      2006   Phase 2   NCT00324454   United States
Levosimendan
   Orion Corporation Orion Pharma
      2015   Phase 2   EUCTR2014-004567-21-NL   Germany;Ireland;Netherlands;United Kingdom
      2015   Phase 2   EUCTR2014-004567-21-IE   Germany;Ireland;Netherlands;United Kingdom
      2015   Phase 2   EUCTR2014-004567-21-GB   Germany;Ireland;Netherlands;United Kingdom
      2015   Phase 2   EUCTR2014-004567-21-DE   Germany;Ireland;Netherlands;United Kingdom
   Orion Corporation, Orion Pharma
      2019   Phase 3   NCT03948178   Spain
      2018   Phase 3   NCT03505021   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
Lioresal*50CPR 10MG
   AZIENDA OSPEDALIERO-UNIVERSITARIA
      2010   -   EUCTR2010-020257-13-IT   Italy
Lipoic acid group
   Second Affiliated Hospital, School of Medicine, Zhejiang University
      2020   -   NCT04518540   China
Liposomed polyphenols resveratrol and curcumin
   Fundación Universidad Católica de Valencia San Vicente Mártir
      2021   Phase 2   NCT04654689   Spain
Lithium
   AZIENDA OSPEDALIERA PISANA
      2009   -   EUCTR2009-010060-41-IT   Italy
   AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO
      2008   -   EUCTR2008-001094-15-IT   Italy
   Assistance Publique - Hôpitaux de Paris
      2009   Phase 2   NCT00925847   France
   I.N.M. NEUROMED (I.R.C.C.S.) S.R.L. GIA' SANATRIX
      2007   -   EUCTR2007-002379-16-IT   Italy
   ISTITUTO SUPERIORE DI SANITA`
      2009   -   EUCTR2008-006722-34-IT   Italy
Lithium apogepha
   King's College London
      2009   Phase 4   EUCTR2008-006891-31-GB   United Kingdom
Lithium carbonate
   Forbes Norris MDA/ALS Research Center
      2008   Phase 2   NCT00790582   United States
   Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
      2009   -   EUCTR2008-006224-61-ES   Spain
   King's College London
      2009   Phase 4   EUCTR2008-006891-31-GB   United Kingdom
   Lucia Galan Hospital Clinico San Carlos
      2009   -   EUCTR2008-005106-38-ES   Spain
   Massachusetts General Hospital
      2009   Phase 2/Phase 3   NCT00818389   Canada;United States
   Prof. dr L.H. van den Berg, UMC-Utrecht
      2008   -   EUCTR2008-002110-22-NL   Netherlands
   Stichting TRICALS Foundation
      2022   Phase 3   EUCTR2020-000579-19-ES   Australia;Belgium;Ireland;Netherlands;Spain;Sweden;United Kingdom
      2021   Phase 3   EUCTR2020-000579-19-NL   Australia;Belgium;Netherlands;Spain;Sweden;United Kingdom
      2021   Phase 3   EUCTR2020-000579-19-BE   Australia;Belgium;Ireland;Netherlands;Spain;Sweden;United Kingdom
Lithium carbonate 400 MG
   Stichting TRICALS Foundation
      2021   Phase 3   NCT06008249   Australia;Belgium;Netherlands;Spain;Sweden;United Kingdom
Lithium citrate
   King's College London
      2009   Phase 4   EUCTR2008-006891-31-GB   United Kingdom
Lithiumcarbonaat 400 PCH tabletten
   Prof. dr L.H. van den Berg, UMC-Utrecht
      2008   -   EUCTR2008-002110-22-NL   Netherlands
Litio carbonato
   AZIENDA OSPEDALIERA PISANA
      2009   -   EUCTR2009-010060-41-IT   Italy
   Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
      2009   -   EUCTR2008-006224-61-ES   Spain
   Lucia Galan Hospital Clinico San Carlos
      2009   -   EUCTR2008-005106-38-ES   Spain
Lunasin regimen
   Richard Bedlack, M.D., Ph.D.
      2016   Phase 2   NCT02709330   United States
MAAT033
   MaaT Pharma
      2023   Phase 1   NCT05889572   France
Mannitolo 18% LDB
   Università degli Studi di Torino e Azienda Ospedaliera Città della Salute e della Scienza di Torino
      2014   Phase 2   EUCTR2014-002228-28-IT   Italy
Masitinib
   AB Science
      2021   Phase 3   NCT03127267   Belgium;Canada;Denmark;France;Germany;Greece;Israel;Italy;Norway;Poland;Portugal;Russian Federation;Serbia;Slovenia;Spain;Sweden;Ukraine;United States
      2013   Phase 2/Phase 3   NCT02588677   Spain
Masitinib 100 MG tablets
   AB Science
      -   Phase 2;Phase 3   EUCTR2010-024423-24-IE   Argentina;Belgium;Colombia;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Netherlands;Portugal;Romania;Slovakia;Spain;Switzerland;United Kingdom;United States
Masitinib 100MG
   AB Science
      -   Phase 3   EUCTR2019-001862-13-IE   Argentina;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;United Kingdom;United States
      -   Phase 3   EUCTR2019-001862-13-GB   Argentina;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;United Kingdom;United States
Masitinib 200 MG tablets
   AB Science
      -   Phase 2;Phase 3   EUCTR2010-024423-24-IE   Argentina;Belgium;Colombia;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Netherlands;Portugal;Romania;Slovakia;Spain;Switzerland;United Kingdom;United States
Masitinib 200MG
   AB Science
      -   Phase 3   EUCTR2019-001862-13-IE   Argentina;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;United Kingdom;United States
      -   Phase 3   EUCTR2019-001862-13-GB   Argentina;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;United Kingdom;United States
Masitinib mesilate
   AB SCIENCE
      2021   Phase 3   EUCTR2019-001862-13-IT   Argentina;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;Ukraine;United Kingdom;United States
Masitinib mesylate
   AB SCIENCE
      2015   Phase 2;Phase 3   EUCTR2010-024423-24-IT   Argentina;Colombia;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Netherlands;Portugal;Romania;Serbia;Slovakia;Spain;United Kingdom
   AB Science
      2022   Phase 3   EUCTR2019-001862-13-GR   Argentina;Belgium;Canada;Denmark;France;Greece;Ireland;Israel;Italy;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2019-001862-13-NO   Argentina;Belgium;Canada;Denmark;France;Greece;Ireland;Israel;Italy;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2019-001862-13-DK   Argentina;Belgium;Canada;Denmark;France;Greece;Ireland;Israel;Italy;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2019-001862-13-SE   Argentina;Belgium;Canada;Denmark;France;Greece;Ireland;Israel;Italy;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2019-001862-13-PL   Argentina;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;Ukraine;United Kingdom;United States
      -   Phase 3   EUCTR2019-001862-13-IE   Argentina;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;United Kingdom;United States
      -   Phase 3   EUCTR2019-001862-13-GB   Argentina;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;United Kingdom;United States
      -   Phase 2;Phase 3   EUCTR2010-024423-24-IE   Argentina;Belgium;Colombia;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Netherlands;Portugal;Romania;Slovakia;Spain;Switzerland;United Kingdom;United States
   ABScience
      2022   Phase 3   EUCTR2019-001862-13-PT   Argentina;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2019-001862-13-BE   Argentina;Belgium;Canada;Denmark;France;Greece;Ireland;Israel;Italy;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2019-001862-13-SI   Argentina;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2019-001862-13-FR   Argentina;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2019-001862-13-ES   Argentina;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;United Kingdom;United States
      2015   Phase 2;Phase 3   EUCTR2010-024423-24-PT   Argentina;Colombia;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Netherlands;Portugal;Romania;Serbia;Slovakia;Spain;United Kingdom;United States
      2015   Phase 2;Phase 3   EUCTR2010-024423-24-NL   Argentina;Colombia;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Netherlands;Portugal;Romania;Serbia;Slovakia;Spain;United Kingdom;United States
      2015   Phase 2;Phase 3   EUCTR2010-024423-24-HU   Argentina;Belgium;Colombia;Czech Republic;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Mexico;Netherlands;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Taiwan;United Kingdom;United States
      2015   Phase 2;Phase 3   EUCTR2010-024423-24-GR   Argentina;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;United States
      2014   Phase 2;Phase 3   EUCTR2010-024423-24-SK   Argentina;Colombia;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Netherlands;Portugal;Romania;Serbia;Slovakia;Spain;United Kingdom;United States
      2013   Phase 2   EUCTR2010-024423-24-ES   France;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain
MCI-186
   Mitsubishi Tanabe Pharma Corporation
      2007   Phase 3   NCT00424463   Japan
      2006   Phase 3   NCT00415519   Japan
      2006   Phase 3   NCT00330681   Japan
MCI-186 IN open label phase
   Mitsubishi Tanabe Pharma Corporation
      2011   Phase 3   NCT01492686   Japan
MD1003
   MEDDAY PHARMACEUTICALS
      2016   Phase 2   EUCTR2015-005810-31-FR   France
   MedDay Pharmaceuticals SA
      2016   Phase 2   NCT03114215   France
Mecobalamin
   Eisai Co., Ltd.
      2008   Phase 2/Phase 3   NCT00445172   Japan
      2007   Phase 2/Phase 3   NCT00444613   Japan
Medicabilis CBD OIL
   Gold Coast Hospital and Health Service
      2021   Phase 4   NCT04997954   Australia
      2019   Phase 3   NCT03690791   Australia
Megestrol
   Dahua Hospital
      2018   -   ChiCTR1800016626   China
Melatonin
   Duke University
      2024   Phase 2   NCT06429059   United States
Memantine
   Phoenix Neurological Associates, LTD
      2005   Phase 2   NCT01020331   United States
   University of Alberta
      2007   Phase 2   NCT00409721   Canada
   University of Kansas Medical Center
      2018   Phase 2   NCT02118727   United States
   University of Lisbon
      2005   Phase 2/Phase 3   NCT00353665   Portugal
Memantine hydrochloride
   Jorge Matias-Guiu Guia
      2008   -   EUCTR2007-002117-39-ES   Spain
Memantine hydrochloride oral solution
   University of Edinburgh
      2020   Phase 2/Phase 3   NCT04302870   United Kingdom
Mesenchymal stem cell
   Alzahra Hospital, Iran
      2015   Phase 1/Phase 2   NCT02116634   Iran, Islamic Republic of
Mesenchymal stem cells
   Hadassah Medical Organization
      2016   Phase 1/Phase 2   NCT04821479   -
   Royan Institute
      2014   Phase 1   NCT02492516   Iran, Islamic Republic of
Mesenchymal stem cells isolated from wharton'S jelly
   Polski Bank Komorek Macierzystych JSC (PBKM)
      2020   Phase 1/Phase 2   NCT04651855   Poland
Metformin
   University of Florida
      2020   Phase 2   NCT04220021   United States
Methylcobalamin
   Eisai Co., Ltd.
      2017   Phase 3   NCT03548311   Japan
Methylphenylpyrazolone
   Ferrer Internacional S.A.
      2021   Phase 3   EUCTR2020-003376-40-IT   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom
Methylprednisolone
   Emory University
      2013   Phase 2   NCT01884571   United States
Mexiletine
   Bjorn Oskarsson, MD
      2013   Phase 4   NCT01811355   United States
   Department of Neurology, Graduate School of Medicine, Chiba University, Japan.
      2011   -   JPRN-UMIN000006423   Japan
   University of Washington
      2016   Phase 2   NCT02781454   United States
      2013   Phase 2   NCT01849770   United States
Micro mouth pressure meter
   University of Florida
      2016   Early Phase 1   NCT02710162   United States
      2016   Early Phase 1   NCT02710110   United States
Midazolam
   Genentech, Inc.
      2016   Phase 1   NCT02655614   Canada;Netherlands;United States
Minocycline
   Columbia University
      2006   Phase 2   NCT00355576   United States
Mitoq
   Duke University
      2024   Phase 2   NCT06429059   United States
MN-166
   MediciNova
      2020   Phase 2/Phase 3   NCT04057898   Canada;United States
      2014   Phase 2   NCT02238626   United States
   MediciNova, Inc.
      2020   Phase 2;Phase 3   EUCTR2019-003549-14-HU   Germany;Greece;Hungary;Italy;Poland;Spain;United States
Monitor
   Osaka University
      2009   -   JPRN-UMIN000002276   Japan
Monthly autologous treg cells infusions + 3 times PER week interleukin-2 injections
   The Methodist Hospital Research Institute
      2019   Phase 2   NCT04055623   United States
Moxifloxacin
   Knopp Biosciences
      2012   Phase 1   NCT01511029   United States
MRG-001
   MedRegen LLC
      2025   Phase 2   NCT06315608   -
Msc_ntf cells transplantation BY multiple intramuscular injections AT 24 separate sites, IN addition TO A single intrathechal injection into THE CSF
   Brainstorm-Cell Therapeutics
      2012   Phase 2   NCT01777646   Israel
MT-1186
   Mitsubishi Tanabe Development America Inc.
      2021   Phase 3   EUCTR2020-000376-38-IT   Canada;France;Germany;Italy;Japan;United States
      2021   Phase 3   EUCTR2019-004256-11-IT   Canada;France;Germany;Italy;Japan;Korea, Republic of;Switzerland;United States
      2020   Phase 3   EUCTR2019-002108-41-IT   Canada;France;Germany;Italy;Japan;United States
   Mitsubishi Tanabe Pharma America Inc.
      2022   Phase 3   NCT05151471   Canada;Germany;Japan;Korea, Republic of;Switzerland;United Kingdom;United States
      2020   Phase 3   NCT04577404   Canada;France;Germany;Italy;Japan;United States
      2020   Phase 3   NCT04569084   Canada;Germany;Italy;Japan;Korea, Republic of;Switzerland;United States
   Mitsubishi Tanabe Pharma America, Inc. (MTPA)
      2022   Phase 3   EUCTR2021-003900-42-DE   Canada;Germany;Italy;Japan;Korea, Republic of;Switzerland;United States
   Mitsubishi Tanabe Pharma Corporation
      2022   Phase 3   NCT05568615   Japan
      2020   Phase 1   NCT04254913   Japan
      2019   Phase 1   NCT04176224   Japan
   Mitsubishi Tanabe Pharma Development America, Inc.
      2021   Phase 3   EUCTR2020-000376-38-FR   Canada;France;Germany;Italy;Japan;United States
      2021   Phase 3   EUCTR2020-000376-38-DE   Canada;France;Germany;Italy;Japan;United States
      2020   Phase 3   EUCTR2019-002108-41-DE   Canada;France;Germany;Italy;Japan;United States
   Mitsubishi Tanabe Pharma Development America, Inc. (MTDA)
      2021   Phase 3   EUCTR2019-004256-11-DE   Canada;Germany;Italy;Japan;Korea, Republic of;Switzerland;United States
Multiple ascending doses OF QRL-201
   QurAlis Corporation
      2022   Phase 1   NCT05633459   Belgium;Canada;Germany;Ireland;Netherlands;United Kingdom
Multiple dose
   Knopp Biosciences
      2011   Phase 1   NCT01424163   United Kingdom
Mycophenolate mofetil
   Emory University
      2013   Phase 2   NCT01884571   United States
Myelostim 34*1FL 263MCG+1SIR
   AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO
      2005   -   EUCTR2005-003248-75-IT   Italy
Myonal*30CPR RIV 100MG
   AZIENDA OSPEDALIERO-UNIVERSITARIA
      2010   -   EUCTR2010-020257-13-IT   Italy
Nerve growth factor
   Beijing Tiantan Hospital
      2024   Phase 2/Phase 3   NCT06391645   -
Nicotinamide riboside
   Haukeland University Hospital
      2021   -   NCT05095571   Norway
      2020   -   NCT04562831   Norway
NL-chchd-001
   n-Lorem Foundation
      2024   Phase 1/Phase 2   NCT06392126   United States
Norantipyrine
   Ferrer Internacional S.A.
      2021   Phase 3   EUCTR2020-003376-40-IT   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom
Norphenazone
   Ferrer Internacional S.A.
      2021   Phase 3   EUCTR2020-003376-40-IT   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom
NP001
   Neuraltus Pharmaceuticals, Inc.
      2016   Phase 2   NCT02794857   Canada;United States
      2011   Phase 2   NCT01281631   United States
      2010   Phase 1   NCT01091142   United States
   Novabio Therapeutics
      2024   Phase 1   NCT06671236   China;United States
Nuedexta
   Center for Neurologic Study, La Jolla, California,
      2013   Phase 2   NCT01806857   United States
NX210C
   Axoltis Pharma
      2024   Phase 2   NCT06365216   France
ODM-109
   ORION CORPORATION ORION PHARMA
      2019   Phase 3   EUCTR2018-004180-31-IT   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2018   Phase 3   EUCTR2017-002754-36-IT   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
   Orion Corporation
      2020   Phase 3   EUCTR2018-004180-31-FR   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004180-31-NL   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004180-31-IE   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004180-31-GB   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004180-31-FI   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004180-31-ES   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004180-31-DE   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004180-31-BE   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004180-31-AT   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2019   Phase 3   EUCTR2017-002754-36-FR   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2018   Phase 3   EUCTR2017-002754-36-NL   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2018   Phase 3   EUCTR2017-002754-36-IE   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2018   Phase 3   EUCTR2017-002754-36-GB   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2018   Phase 3   EUCTR2017-002754-36-FI   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2018   Phase 3   EUCTR2017-002754-36-ES   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2018   Phase 3   EUCTR2017-002754-36-BE   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2018   Phase 3   EUCTR2017-002754-36-AT   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
   Orion Corporation, Orion Pharma
      2015   Phase 2   NCT02487407   Germany;Ireland;Netherlands;United Kingdom
ODM-109 capsule 1 MG
   Orion Corporation Orion Pharma
      2015   Phase 2   EUCTR2014-004567-21-NL   Germany;Ireland;Netherlands;United Kingdom
      2015   Phase 2   EUCTR2014-004567-21-IE   Germany;Ireland;Netherlands;United Kingdom
      2015   Phase 2   EUCTR2014-004567-21-GB   Germany;Ireland;Netherlands;United Kingdom
      2015   Phase 2   EUCTR2014-004567-21-DE   Germany;Ireland;Netherlands;United Kingdom
Olanzapine
   Charite University, Berlin, Germany
      2011   Phase 2/Phase 3   NCT00876772   Germany
   Charité – Universitätsmedizin Berlin
      2008   -   EUCTR2007-003775-39-DE   Germany
Olesoxime
   Hoffmann-La Roche
      2009   Phase 3   NCT00868166   Belgium;France;Germany;Netherlands;Spain;United Kingdom
   TROPHOS
      2011   -   EUCTR2010-021179-10-GB   Germany;Spain;United Kingdom
      2009   Phase 2;Phase 3   EUCTR2008-007320-25-GB   Belgium;France;Germany;Spain;United Kingdom
   TROPHOS SA
      2011   -   EUCTR2010-021179-10-DE   Germany;Spain;United Kingdom
      2011   Phase 2;Phase 3   EUCTR2010-021179-10-BE   Belgium;Germany;Spain;United Kingdom
      2009   Phase 2;Phase 3   EUCTR2008-007320-25-FR   Belgium;France;Germany;Spain;United Kingdom
      2009   Phase 2   EUCTR2008-007320-25-ES   Belgium;France;Germany;Spain;United Kingdom
      2009   -   EUCTR2008-007320-25-DE   Belgium;France;Germany;Spain;United Kingdom
      2009   Phase 2;Phase 3   EUCTR2008-007320-25-BE   Belgium;France;Germany;Spain;United Kingdom
ONO-2506
   ONO PHARMA UK LTD
      2007   -   EUCTR2006-002660-26-IT   Austria;Belgium;France;Germany;Italy;Netherlands;United Kingdom
   ONO Pharmaceutical Co.,Ltd
      2007   -   EUCTR2006-002660-26-NL   Austria;Belgium;France;Germany;Italy;Netherlands;United Kingdom
      2007   -   EUCTR2006-002660-26-GB   Austria;Belgium;France;Germany;Italy;Netherlands;United Kingdom
      2006   Phase 2   EUCTR2006-002660-26-FR   Austria;Belgium;France;Germany;Italy;Netherlands;United Kingdom
      2006   -   EUCTR2006-002660-26-DE   Austria;Belgium;France;Germany;Italy;Netherlands;United Kingdom
      2006   -   EUCTR2006-002660-26-BE   Austria;Belgium;France;Germany;Italy;Netherlands;United Kingdom
      2006   -   EUCTR2006-002660-26-AT   Austria;Belgium;France;Germany;Italy;Netherlands;United Kingdom
ONO-2506PO
   ONO PHARMA UK LTD
      2004   Phase 2   EUCTR2004-002912-27-ES   Spain
   ONO Pharmaceutical Co., Ltd.
      2008   -   EUCTR2007-004723-37-GB   Belgium;France;Germany;United Kingdom
      2008   Phase 2   EUCTR2007-004723-37-FR   Belgium;France;Germany;United Kingdom
      2008   -   EUCTR2007-004723-37-DE   Belgium;France;Germany;United Kingdom
      2008   -   EUCTR2007-004723-37-BE   Belgium;France;Germany;United Kingdom
   ONO Pharmaceutical Co.,Ltd
      2007   -   EUCTR2006-002660-26-NL   Austria;Belgium;France;Germany;Italy;Netherlands;United Kingdom
      2007   -   EUCTR2006-002660-26-GB   Austria;Belgium;France;Germany;Italy;Netherlands;United Kingdom
      2006   Phase 2   EUCTR2006-002660-26-FR   Austria;Belgium;France;Germany;Italy;Netherlands;United Kingdom
      2006   -   EUCTR2006-002660-26-DE   Austria;Belgium;France;Germany;Italy;Netherlands;United Kingdom
      2006   -   EUCTR2006-002660-26-BE   Austria;Belgium;France;Germany;Italy;Netherlands;United Kingdom
      2006   -   EUCTR2006-002660-26-AT   Austria;Belgium;France;Germany;Italy;Netherlands;United Kingdom
   Ono Pharmaceutical Co. Ltd
      2008   Phase 2   NCT00694941   Belgium;France;Germany;Italy;Netherlands;Switzerland;United Kingdom
      2006   Phase 2   NCT00403104   Austria;Belgium;France;Germany;Italy;Netherlands;Switzerland;United Kingdom
Oral levosimendan
   ORION CORPORATION ORION PHARMA
      2019   Phase 3   EUCTR2018-004180-31-IT   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2018   Phase 3   EUCTR2017-002754-36-IT   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
   Orion Corporation
      2020   Phase 3   EUCTR2018-004180-31-FR   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004180-31-NL   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004180-31-IE   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004180-31-GB   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004180-31-FI   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004180-31-ES   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004180-31-DE   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004180-31-BE   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004180-31-AT   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2019   Phase 3   EUCTR2017-002754-36-FR   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2018   Phase 3   EUCTR2017-002754-36-NL   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2018   Phase 3   EUCTR2017-002754-36-IE   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2018   Phase 3   EUCTR2017-002754-36-GB   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2018   Phase 3   EUCTR2017-002754-36-FI   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2018   Phase 3   EUCTR2017-002754-36-ES   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2018   Phase 3   EUCTR2017-002754-36-BE   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2018   Phase 3   EUCTR2017-002754-36-AT   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
Oral nutritional supplementation
   University Hospital, Limoges
      2014   -   NCT02152449   France
ORT247
   Orthogonal Neuroscience Inc.
      2022   Phase 1   NCT06769620   United States
Oxaloacetic acid
   Omar Jawdat
      2020   Phase 1   NCT04204889   United States
Oxepa
   Massachusetts General Hospital
      2009   Phase 2   NCT00983983   United States
Ozanezumab
   GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.
      2012   -   EUCTR2012-003349-13-IT   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States
   GlaxoSmithKline
      2012   Phase 2   NCT01753076   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States
   GlaxoSmithKline Research and Development Limited
      2013   -   EUCTR2012-003349-13-NL   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States
      2013   -   EUCTR2012-003349-13-DE   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States
      2012   Phase 2   EUCTR2012-003349-13-GB   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States
      2012   Phase 2   EUCTR2012-003349-13-FR   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States
      2012   -   EUCTR2012-003349-13-BE   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States
Palmitoylethanolamide
   University of Roma La Sapienza
      2014   -   NCT02645461   -
Paracetamolo
   Università degli Studi di Torino e Azienda Ospedaliera Città della Salute e della Scienza di Torino
      2014   Phase 2   EUCTR2014-002228-28-IT   Italy
Pbmc autotransplantation
   The First Affiliated Hospital of Dalian Medical University
      2010   -   NCT03085706   China
Pegcetacoplam
   APELLIS PHARMACEUTCIALS, INC.
      2021   Phase 2   EUCTR2019-003797-10-IT   Argentina;Australia;Belgium;Brazil;Czech Republic;Czechia;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States
Pegcetacoplan
   Apellis Pharmaceuticals, Inc.
      2021   Phase 2   EUCTR2019-003797-10-NL   Argentina;Australia;Belgium;Brazil;Czech Republic;Czechia;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States
      2021   Phase 2   EUCTR2019-003797-10-IE   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Czechia;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States
      2021   Phase 2   EUCTR2019-003797-10-DE   Argentina;Australia;Belgium;Brazil;Czech Republic;Czechia;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States
      2021   Phase 2   EUCTR2019-003797-10-CZ   Argentina;Australia;Belgium;Brazil;Czech Republic;Czechia;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States
      2020   Phase 2   NCT04579666   Australia;Belgium;Czechia;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States
   Kreisl Chuck
      2021   Phase 2   JPRN-jRCT2031230170   Argentina;Australia;Blgium;Brazil;Czechia;France;Germany;Ireland;Italy;Japan;Netherland;Poland;Spain;UK;US;Ukraine
Perampanel
   Department of Neurology, Juntendo University School of Medicine
      2017   Phase 1   JPRN-UMIN000026221   Japan
   Department of Neurology, Tokyo Medical University
      2017   Phase 2   JPRN-UMIN000025614   Japan
   Mayo Clinic
      2018   Early Phase 1   NCT03793868   United States
   Stony Brook University
      2017   -   NCT03020797   United States
   Tokyo Medical University
      2017   Phase 2   NCT03019419   Japan
Perfalgan
   Università degli Studi di Torino e Azienda Ospedaliera Città della Salute e della Scienza di Torino
      2014   Phase 2   EUCTR2014-002228-28-IT   Italy
Phenylbutyrate
   Amylyx Pharmaceuticals Inc.
      2023   Phase 3   EUCTR2022-002348-33-PT   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2023   Phase 3   EUCTR2022-002348-33-PL   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2023   Phase 3   EUCTR2022-002348-33-FR   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2023   Phase 3   EUCTR2022-002348-33-BE   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2022   Phase 3   EUCTR2022-002348-33-NL   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2022   Phase 3   EUCTR2022-002348-33-ES   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-000250-26-PT   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-000250-26-PL   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-000250-26-BE   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2021   Phase 3   EUCTR2021-000250-26-SE   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2021   Phase 3   EUCTR2021-000250-26-NL   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2021   Phase 3   EUCTR2021-000250-26-FR   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2021   Phase 3   EUCTR2021-000250-26-DE   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
Pimozide
   University of Calgary
      2017   Phase 2   NCT03272503   Canada
Pimozide 2 MG PER DAY
   University of Calgary
      2015   Phase 2   NCT02463825   Canada
Pimozide 4 MG PER DAY
   University of Calgary
      2015   Phase 2   NCT02463825   Canada
Pioglitazone
   University Hospital of Ulm
      2008   -   EUCTR2006-005410-13-DE   Germany
   University of Ulm
      2008   Phase 2   NCT00690118   Germany;Italy
Pioglitazone and tretinoin
   Phoenix Neurological Associates, LTD
      2008   Phase 1/Phase 2   NCT00919555   United States
Plasma from healthy young people treatment + riluzole
   Peking University Third Hospital
      2016   Early Phase 1   NCT04454840   China
Pleconaril
   Apodemus AB
      2014   Phase 2   EUCTR2012-002099-15-SE   Sweden
Plenur
   Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
      2009   -   EUCTR2008-006224-61-ES   Spain
   Lucia Galan Hospital Clinico San Carlos
      2009   -   EUCTR2008-005106-38-ES   Spain
PLL001
   PLL TX AUSTRALIA PTY LTD
      2024   Phase 1/Phase 2   NCT06513546   -
Polymva
   University of Missouri-Columbia
      2020   Phase 1   NCT04557410   United States
Powerlung trainer
   University of Florida
      2016   Early Phase 1   NCT02710110   United States
PR1
   Hospices Civils de Lyon
      2011   Phase 2   EUCTR2010-023161-21-FR   France
Prednisone
   Emory University
      2013   Phase 2   NCT01884571   United States
Pridopidine
   Merit E. Cudkowicz, MD
      2020   Phase 2/Phase 3   NCT04615923   United States
   Prilenia
      2022   -   NCT06069934   Puerto Rico;United States
Primec
   NeuroSense Therapeutics Ltd
      2022   Phase 2   EUCTR2022-002185-32-IT   Israel;Italy;United States
   NeuroSense Therapeutics Ltd.
      2022   Phase 2   NCT05357950   Canada;Israel;Italy;United States
Primidone
   The First People's Hospital of Yichang
      2022   Phase 2   ChiCTR2200058224   China
Probiotic
   Avera McKennan Hospital & University Health Center
      2017   -   NCT03324399   United States
   Centre hospitalier de l'Université de Montréal (CHUM)
      2024   -   NCT06051123   Canada
Proleukin
   The Methodist Hospital Research Institute
      2021   Phase 1   NCT06307301   United States
Proleukin 18 MUI
   CHU DE NIMES
      2016   Phase 2   EUCTR2015-005347-14-GB   United Kingdom
Prosetin
   ProJenX
      2022   Phase 1   NCT05279755   Canada;Netherlands;United States
Protandim
   Duke University
      2024   Phase 2   NCT06429059   United States
Prototype capsule GDC-0134
   Genentech, Inc.
      2017   Phase 1   NCT03237741   United Kingdom
Psilocybin
   Johns Hopkins University
      2025   Early Phase 1   NCT06656702   United States
Psilocybin therapy
   University Medical Center Groningen
      2025   Phase 2   NCT06782724   -
PTC857
   PTC Therapeutics
      2022   Phase 2   NCT05349721   Argentina;Australia;Belgium;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Spain;Sweden;United States
   PTC Therapeutics, Inc.
      2022   Phase 2   EUCTR2021-006511-29-DE   Argentina;Australia;Belgium;Brazil;Czech Republic;Czechia;France;Germany;Ireland;Italy;Japan;Mexico;Netherlands;Norway;Poland;Spain;Sweden;United States
      2022   Phase 2   EUCTR2021-006511-29-BE   Argentina;Australia;Belgium;Brazil;Czech Republic;Czechia;France;Germany;Ireland;Italy;Japan;Mexico;Netherlands;Norway;Poland;Spain;Sweden;United States
PTC857 60 MG/ML oral solution
   PTC Therapeutics, Inc.
      2023   Phase 2   EUCTR2021-006511-29-SE   Argentina;Australia;Belgium;Brazil;Czech Republic;Czechia;France;Germany;Ireland;Italy;Japan;Mexico;Netherlands;Norway;Poland;Spain;Sweden;United States
      2023   Phase 2   EUCTR2021-006511-29-NO   Argentina;Australia;Belgium;Brazil;Czech Republic;Czechia;France;Germany;Ireland;Italy;Japan;Mexico;Netherlands;Norway;Poland;Spain;Sweden;United States
      2023   Phase 2   EUCTR2021-006511-29-NL   Argentina;Australia;Belgium;Brazil;Czech Republic;Czechia;France;Germany;Ireland;Italy;Japan;Mexico;Netherlands;Norway;Poland;Spain;Sweden;United States
      2023   Phase 2   EUCTR2021-006511-29-CZ   Argentina;Australia;Belgium;Brazil;Czech Republic;Czechia;France;Germany;Ireland;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Spain;Sweden;United States
PTC857 oral solution
   PTC Therapeutics, Inc.
      2023   Phase 2   EUCTR2021-006511-29-PL   Argentina;Australia;Belgium;Brazil;Czech Republic;Czechia;France;Germany;Ireland;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Spain;Sweden;United States
      2022   Phase 2   EUCTR2021-006511-29-FR   Argentina;Australia;Belgium;Brazil;Czech Republic;Czechia;France;Germany;Italy;Japan;Mexico;Netherlands;Norway;Poland;Spain;Sweden;United States
Pterostilbene
   Haukeland University Hospital
      2021   -   NCT05095571   Norway
      2020   -   NCT04562831   Norway
PU-AD
   Samus Therapeutics, Inc.
      2023   Phase 2   NCT04505358   -
Pulmonary function testing
   University of Florida
      2017   -   NCT02962050   United States
      2016   Early Phase 1   NCT02710162   United States
      2016   Early Phase 1   NCT02710110   United States
Pyrimethamine
   Weill Medical College of Cornell University
      2013   -   EUCTR2011-004798-99-DE   Germany;Italy;United States
      2009   Phase 1/Phase 2   NCT01083667   Germany;Italy;Sweden;United States
Q-cells
   Q Therapeutics, Inc.
      2024   Phase 1/Phase 2   NCT02478450   -
QRL-101
   QurAlis Corporation
      2024   Phase 1   NCT06714396   Netherlands
R(+) pramipexole dihydrochloride monohydrate
   Bennett, James P., Jr., M.D., Ph.D.
      2007   Phase 1/Phase 2   NCT00600873   United States
      2005   -   NCT00596115   -
      2005   Phase 1/Phase 2   NCT00140218   United States
RA15804589, C19061501-F, DNL788, DN2489, DN0002489
   SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
      2022   Phase 2   EUCTR2021-004156-42-IT   Belgium;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
   Sanofi-aventis recherche & développement
      2023   Phase 2   EUCTR2021-004156-42-PL   Belgium;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2022   Phase 2   EUCTR2021-004156-42-SE   Belgium;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2022   Phase 2   EUCTR2021-004156-42-NL   Belgium;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2022   Phase 2   EUCTR2021-004156-42-FR   Belgium;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2022   Phase 2   EUCTR2021-004156-42-ES   Belgium;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2022   Phase 2   EUCTR2021-004156-42-DE   Belgium;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2022   Phase 2   EUCTR2021-004156-42-BE   Belgium;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
Rabeprazole
   Genentech, Inc.
      2017   Phase 1   NCT03237741   United Kingdom
      2016   Phase 1   NCT02655614   Canada;Netherlands;United States
RAG-17
   Beijing Tiantan Hospital
      2023   Early Phase 1   NCT05903690   China
   Ractigen Therapeutics.
      2024   Phase 1   NCT06556394   China
Ranolazine
   Swathy Chandrashekhar, MD
      2025   Phase 2   NCT06527222   United States
Ranolazine 1000 MG
   University of Kansas Medical Center
      2018   Phase 2   NCT03472950   United States
Ranolazine 500 MG
   University of Kansas Medical Center
      2018   Phase 2   NCT03472950   United States
RAPA-501 autologous T stem cells
   Rapa Therapeutics LLC
      2025   Phase 2/Phase 3   NCT04220190   United States
Rapamune - 1 MG 100 compresse rivestite IN blister USO orale
   AZIENDA OSPEDALIERO-UNIVERSITARIA POLICLINICO DI MODENA
      2017   Phase 2   EUCTR2016-002399-28-IT   Italy
Rapamycin
   Azienda Ospedaliero-Universitaria di Modena
      2017   Phase 2   NCT03359538   Italy
Rasagiline
   Richard Barohn, MD
      2013   Phase 2   NCT01786603   United States
   University of Ulm
      2013   Phase 2   NCT01879241   Germany
   Yunxia Wang, MD
      2011   Phase 2   NCT01232738   Canada;United States
Rasagiline mesilate
   Universitätsklinikum Ulm
      2013   Phase 2   EUCTR2011-004482-32-DE   Germany
Ravulizumab
   ALEXION PHARMACEUTICALS INCORPORATED
      2020   Phase 3   EUCTR2019-004619-30-IT   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
   Alexion Pharmaceuticals
      2020   Phase 3   NCT04248465   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004619-30-SE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004619-30-NL   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004619-30-IE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004619-30-GB   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004619-30-FR   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004619-30-ES   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004619-30-DK   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004619-30-DE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
Reference capsule GDC-0134
   Genentech, Inc.
      2017   Phase 1   NCT03237741   United Kingdom
Reldesemtiv
   CYTOKINETICS, INC.
      2023   Phase 3   EUCTR2021-004727-33-IT   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004040-29-IT   Australia;Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
   Cytokinetics
      2022   Phase 3   NCT05442775   Australia;Belgium;Canada;Ireland;Italy;Netherlands;Spain;Sweden;United States
      2021   Phase 3   NCT04944784   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
      2017   Phase 2   NCT03160898   Australia;Canada;Ireland;Netherlands;Spain;United States
   Cytokinetics Inc
      2023   Phase 3   EUCTR2021-004727-33-PT   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
      2023   Phase 3   EUCTR2021-004727-33-NL   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
      2023   Phase 3   EUCTR2021-004727-33-DK   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
      2023   Phase 3   EUCTR2021-004727-33-BE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2020-004040-29-PT   Australia;Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2020-004040-29-PL   Australia;Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004040-29-SE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004040-29-NL   Australia;Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004040-29-IE   Australia;Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004040-29-FR   Australia;Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004040-29-ES   Australia;Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004040-29-BE   Australia;Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
      -   Phase 3   EUCTR2021-004727-33-SE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
      -   Phase 3   EUCTR2020-004040-29-DE   Australia;Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
   Cytokinetics, Inc.
      2018   Phase 2   EUCTR2018-000586-37-NL   Australia;Canada;Ireland;Netherlands;Spain;United States
      2018   Phase 2   EUCTR2018-000586-37-IE   Australia;Canada;Ireland;Netherlands;Spain;United States
      2018   Phase 2   EUCTR2018-000586-37-ES   Australia;Canada;Ireland;Netherlands;Spain;United States
Repository corticotropin injection
   Mallinckrodt
      2013   Phase 2   NCT01906658   United States
Retigabine
   Centre for Human Drug Research
      2015   Phase 2   EUCTR2015-001431-20-NL   Netherlands
Ribavirin
   Apodemus AB
      2014   Phase 2   EUCTR2012-002099-15-SE   Sweden
Rilutek
   AZIENDA OSPEDALIERA PISANA
      2009   -   EUCTR2009-010060-41-IT   Italy
   Cytokinetics Inc
      2013   -   EUCTR2012-004987-23-IE   Canada;Germany;Ireland;Netherlands;Spain;United Kingdom;United States
      2013   Phase 2   EUCTR2012-004987-23-GB   Canada;Germany;Ireland;Netherlands;Spain;United Kingdom;United States
      2013   Phase 2   EUCTR2012-004987-23-ES   Canada;France;Germany;Ireland;Netherlands;Spain;United Kingdom;United States
      2013   -   EUCTR2012-004987-23-DE   Canada;Germany;Ireland;Netherlands;Spain;United Kingdom;United States
      -   -   EUCTR2012-004987-23-NL   Canada;France;Germany;Ireland;Netherlands;Spain;United Kingdom;United States
   FeGALS
      2009   -   JPRN-UMIN000008527   Japan
Rilutek 50 MG FILM-coated tablets
   Centre for Human Drug Research
      2015   Phase 2   EUCTR2015-001431-20-NL   Netherlands
Rilutek 50 MG, FILM-coated tablets
   Aventis Pharma Ltd.
      2004   -   EUCTR2004-002390-23-DE   Germany
Riluzole
   AB Science
      2021   Phase 3   NCT03127267   Belgium;Canada;Denmark;France;Germany;Greece;Israel;Italy;Norway;Poland;Portugal;Russian Federation;Serbia;Slovenia;Spain;Sweden;Ukraine;United States
      2013   Phase 2/Phase 3   NCT02588677   Spain
   AZIENDA OSPEDALIERA PISANA
      2009   -   EUCTR2009-010060-41-IT   Italy
   Aventis Pharma Ltd.
      2004   -   EUCTR2004-002390-23-DE   Germany
   Biohaven Pharmaceuticals, Inc.
      2018   -   NCT03537807   -
   Centre Hospitalier Universitaire de Nimes
      2017   Phase 2   NCT03039673   France;United Kingdom
   Centre for Human Drug Research
      2015   Phase 2   EUCTR2015-001431-20-NL   Netherlands
   Corestemchemon, Inc.
      2022   Phase 1   NCT06676423   Korea, Republic of
      2021   Phase 3   NCT04745299   Korea, Republic of
   Cytokinetics
      2012   Phase 2   NCT01709149   Canada;France;Germany;Ireland;Netherlands;Spain;United Kingdom;United States
   Cytokinetics Inc
      2013   -   EUCTR2012-004987-23-IE   Canada;Germany;Ireland;Netherlands;Spain;United Kingdom;United States
      2013   Phase 2   EUCTR2012-004987-23-GB   Canada;Germany;Ireland;Netherlands;Spain;United Kingdom;United States
      2013   Phase 2   EUCTR2012-004987-23-ES   Canada;France;Germany;Ireland;Netherlands;Spain;United Kingdom;United States
      2013   -   EUCTR2012-004987-23-DE   Canada;Germany;Ireland;Netherlands;Spain;United Kingdom;United States
      -   -   EUCTR2012-004987-23-NL   Canada;France;Germany;Ireland;Netherlands;Spain;United Kingdom;United States
   Department of Neurology, Graduate School of Medicine, Chiba University, Japan.
      2011   -   JPRN-UMIN000006423   Japan
   Genuv Inc.
      2020   Phase 1/Phase 2   NCT04326283   Korea, Republic of
   Guangdong Province Traditional Chinese Medical Hospital
      2014   -   ChiCTR-IOR-14005674   China
   Hoffmann-La Roche
      2009   Phase 3   NCT00868166   Belgium;France;Germany;Netherlands;Spain;United Kingdom
   Isfahan University of Medical Sciences
      2017   Phase 2/Phase 3   NCT03272802   Iran, Islamic Republic of
   Massachusetts General Hospital
      2009   Phase 2/Phase 3   NCT00818389   Canada;United States
   MediciNova
      2014   Phase 2   NCT02238626   United States
   Peking University Third Hospital
      2021   Phase 2   ChiCTR2100044085   China
   Sanofi
      2001   Phase 4   NCT00542412   Canada
   Shanghai Sixth People's Hospital
      2020   Phase 0   ChiCTR2000035988   China
   University Affiliated Sixth People's Hospital
      2021   Phase 0   ChiCTR2000028960   China
   University of Lisbon
      2005   Phase 2/Phase 3   NCT00353665   Portugal
   University of Roma La Sapienza
      2014   -   NCT02645461   -
Riluzole 100MG/DAY
   InFlectis BioScience
      2022   Phase 2   NCT05508074   France;Italy
Riluzole 50 MG
   Cytokinetics
      2011   Phase 2   NCT01486849   United States
      2011   Phase 2   NCT01378676   United States
Riluzole oral soluble film
   Aquestive Therapeutics
      2018   Phase 2   NCT03457753   United States
Riluzole oral soluble film (rosf) 50 MG
   Aquestive Therapeutics
      2018   Phase 2   NCT03679975   United States
Riluzole tablet
   Peking University Third Hospital
      2020   Phase 2/Phase 3   NCT04950933   China
Riluzolo
   FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA
      2016   Phase 2   EUCTR2014-005367-32-IT   Italy
Ritonavir
   National Institute of Neurological Disorders and Stroke (NINDS)
      2019   Phase 1   NCT02437110   United States
RJK002 intrathecal injection
   RJK Biopharma Ltd
      2024   Phase 1   NCT06493279   China
      2023   Early Phase 1   NCT06454682   China
RNS60
   IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
      2017   Phase 2   EUCTR2016-002382-62-IT   Italy;United States
   Mario Negri Institute for Pharmacological Research
      2017   Phase 2   NCT03456882   Italy;United States
   Revalesio Corporation
      2026   Phase 2   NCT02988297   -
   Sabrina Paganoni, M.D.
      2015   Phase 1   NCT02525471   United States
RT001
   Retrotope, Inc.
      2021   Phase 2   NCT04762589   Estonia;Latvia;Netherlands;Sweden
      2021   Phase 2   EUCTR2020-003962-38-SE   Estonia;Netherlands;Sweden
      2021   Phase 2   EUCTR2020-003962-38-NL   Estonia;Netherlands;Sweden
      2021   Phase 2   EUCTR2020-003962-38-EE   Estonia;Netherlands;Sweden
RYAH-medtech inhaler
   OMNI Medical Services, LLC
      2018   Phase 2   NCT03944447   United States
Salbutamol
   Assistance Publique - Hôpitaux de Paris
      2024   Phase 2   NCT05860244   France
Saline
   Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
      2021   Phase 2   NCT04849065   Spain
   Red de Terapia Celular
      2014   Phase 1   NCT02286011   Spain
   Talengen Institute of Life Sciences, Shenzhen, P.R. China.
      2024   Phase 1/Phase 2   NCT06726577   China
Saline solution
   Eisai Co., Ltd.
      2017   Phase 3   NCT03548311   Japan
SAR443820
   SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
      2022   Phase 2   EUCTR2021-004156-42-IT   Belgium;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
   Sanofi
      2022   Phase 1   NCT05797753   United States
      2022   Phase 2   NCT05237284   Belgium;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
   Sanofi-aventis recherche & développement
      2023   Phase 2   EUCTR2021-004156-42-PL   Belgium;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2022   Phase 2   EUCTR2021-004156-42-SE   Belgium;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2022   Phase 2   EUCTR2021-004156-42-NL   Belgium;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2022   Phase 2   EUCTR2021-004156-42-FR   Belgium;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2022   Phase 2   EUCTR2021-004156-42-ES   Belgium;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2022   Phase 2   EUCTR2021-004156-42-DE   Belgium;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2022   Phase 2   EUCTR2021-004156-42-BE   Belgium;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
Sativex
   FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR
      2011   -   EUCTR2010-022808-40-IT   Italy
SB-509
   Sangamo Biosciences
      2008   Phase 2   NCT00748501   United States
Scopolamine
   Mie University Graduate school of medicine,Department of neurology
      2013   -   JPRN-UMIN000011494   Japan
Scopolamine, atropine, edaravone and dexmedetomidine
   Ruijin Hospital
      2020   Phase 2   NCT04391361   China
Serotonin
   St. Louis University
      2015   Early Phase 1   NCT02851914   United States
Single dose reduced
   Knopp Biosciences
      2011   Phase 1   NCT01424163   United Kingdom
Single dose standard
   Knopp Biosciences
      2011   Phase 1   NCT01424163   United Kingdom
SIT scoring
   Milton S. Hershey Medical Center
      2022   -   NCT04889898   United States
SLS-005
   Merit E. Cudkowicz, MD
      2022   Phase 2/Phase 3   NCT05136885   United States
SNN0029
   Newron Sweden AB
      2014   Phase 1   NCT01999803   Belgium;Netherlands
      2009   Phase 1/Phase 2   NCT01384162   Belgium
      2008   Phase 1/Phase 2   NCT00800501   Belgium
SNN0029 infusion solution
   Newron Sweden AB
      2015   Phase 1   NCT02269436   Belgium;Netherlands
SNUG01
   Peking University Third Hospital
      2024   Early Phase 1   NCT06645197   China
Sodio phenylbutyrate
   AMYLYX PHARMACEUTICALS Inc.
      2022   Phase 3   EUCTR2022-002348-33-IT   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2021   Phase 3   EUCTR2021-000250-26-IT   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
Sodium chloride
   Yichang Central People's Hospital
      2024   Phase 4   ChiCTR2400082879   China
Sodium phenylbutyrate
   Department of Veterans Affairs
      2005   Phase 1/Phase 2   NCT00107770   United States
   Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
      2021   -   ChiCTR2100051913   China
Sodium pyruvate
   Christoffer Laustsen
      2020   Phase 2   EUCTR2020-000352-36-DK   Denmark
Sodium valproate
   UMC Utrecht
      2005   Phase 3   NCT00136110   Netherlands
Somatropin
   Federico II University
      2007   Phase 2   NCT00635960   Italy
Sotuletinib
   Novartis Pharma AG
      2019   Phase 2   EUCTR2019-000826-22-SE   Australia;Finland;Sweden;United States
      2019   Phase 2   EUCTR2019-000826-22-FI   Australia;Finland;Sweden;United States
SPG302
   Spinogenix
      2025   Phase 2   NCT06903286   Australia
      2023   Phase 1   NCT05882695   Australia;United States
Stem cell
   Neurogen Brain and Spine Institute
      2008   Phase 1   NCT02242071   India
      2008   Phase 2   NCT01984814   India
Stem cell (HPC) implantation
   Cedars-Sinai Medical Center
      2017   Phase 1   NCT02943850   United States
Stem cells
   Stem Cells Arabia
      2016   Phase 1/Phase 2   NCT03067857   -
Stereotactic surgical device
   Cedars-Sinai Medical Center
      2017   Phase 1   NCT02943850   United States
STR04
   New England Cell Therapeutics, Inc.
      2025   Phase 2   NCT06910384   -
SUB126308
   AB Science
      -   Phase 2;Phase 3   EUCTR2010-024423-24-IE   Argentina;Belgium;Colombia;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Netherlands;Portugal;Romania;Slovakia;Spain;Switzerland;United Kingdom;United States
Sulfate
   University of Birmingham
      2018   Phase 2   EUCTR2018-000668-28-GB   United Kingdom
Suspension OF human autologous MSC 3P IN 1,5 ML
   Bioinova, s.r.o.
      2012   Phase 2   EUCTR2011-000362-35-CZ   Czech Republic
Suspension OF human autologous MSC 3P IN 1.5 ML
   Bioinova, s.r.o.
      2012   Phase 1/Phase 2   NCT03828123   -
Swallowing quality OF life questionnaire
   University of Florida
      2016   Early Phase 1   NCT02710110   United States
Swallowing related quality OF life questionnaire
   University of Florida
      2016   Early Phase 1   NCT02710162   United States
Symptomatic treatment OF ALS
   Pomeranian Medical University Szczecin
      2010   Phase 1   NCT02193893   Poland
Synthetic stereopure antisense oligonucleotide targeting human C9orf72 hexanucleotide repeat-containing mrna transcripts
   Wave Life Sciences UK Limited
      2023   Phase 1;Phase 2   EUCTR2022-002267-29-BE   Australia;Belgium;Canada;Ireland;Netherlands;New Zealand;United Kingdom
      2022   Phase 1;Phase 2   EUCTR2020-005193-94-SE   Australia;Belgium;Canada;Germany;Ireland;Netherlands;New Zealand;Sweden;United Kingdom;United States
      2022   Phase 1;Phase 2   EUCTR2020-005193-94-BE   Australia;Belgium;Canada;Germany;Ireland;Netherlands;New Zealand;Sweden;United Kingdom;United States
      2021   Phase 1;Phase 2   EUCTR2020-005193-94-DE   Australia;Belgium;Canada;Germany;Ireland;Netherlands;New Zealand;Sweden;United Kingdom;United States
Tacrolimus
   Emory University
      2013   Phase 2   NCT01884571   United States
Talampanel
   Teva Pharmaceutical Industries
      2009   Phase 2   NCT00982150   Belgium;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;United States
      2008   Phase 2   NCT00696332   Belgium;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;United States
   Teva Pharmaceutical Industries, Ltd
      2008   -   EUCTR2008-002062-62-NL   Belgium;France;Germany;Hungary;Italy;Netherlands;Spain
      2008   -   EUCTR2008-002062-62-HU   Belgium;France;Germany;Hungary;Italy;Netherlands;Spain
      2008   Phase 2   EUCTR2008-002062-62-FR   Belgium;France;Germany;Hungary;Italy;Netherlands;Spain
      2008   Phase 2   EUCTR2008-002062-62-ES   Belgium;France;Germany;Hungary;Italy;Netherlands;Spain
      2008   -   EUCTR2008-002062-62-DE   Belgium;France;Germany;Hungary;Italy;Netherlands;Spain
      2008   -   EUCTR2008-002062-62-BE   Belgium;France;Germany;Hungary;Italy;Netherlands;Spain
   Teva Pharmaceutical Industries,Ltd
      2008   -   EUCTR2008-002062-62-IT   Belgium;France;Germany;Hungary;Italy;Netherlands;Spain
Tallampanel
   Teva Pharmaceutical Industries,Ltd
      2008   -   EUCTR2008-002062-62-IT   Belgium;France;Germany;Hungary;Italy;Netherlands;Spain
Tamoxifen
   Nazem Atassi
      2011   Phase 2   NCT01257581   United States
   University of Wisconsin, Madison
      2001   Phase 2   NCT00214110   United States
Tamoxifen 40 MG daily FOR ONE year
   Taipei Medical University Shuang Ho Hospital
      2014   Phase 1/Phase 2   NCT02166944   Taiwan
Taurolite
   IRCCS ISTITUTO CLINICO HUMANITAS
      2019   Phase 3   EUCTR2018-002722-22-GB   Netherlands;United Kingdom
Tauroursodeoxycholic acid
   AMYLYX PHARMACEUTICALS Inc.
      2021   Phase 3   EUCTR2021-000250-26-IT   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
   Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
      2008   Phase 2   NCT00877604   Italy
   Humanitas Mirasole SpA
      2021   Phase 3   NCT05753852   Belgium;France;Germany;Ireland;Italy;Netherlands;United Kingdom
      2019   Phase 3   NCT03800524   Belgium;France;Germany;Ireland;Italy;Netherlands;United Kingdom
      2019   Phase 3   EUCTR2018-002722-22-NL   Belgium;France;Germany;Italy;Netherlands;United Kingdom
      2019   Phase 3   EUCTR2018-002722-22-IE   Belgium;France;Germany;Ireland;Italy;Netherlands;United Kingdom
      2019   Phase 3   EUCTR2018-002722-22-FR   Belgium;France;Germany;Italy;Netherlands;United Kingdom
      2019   Phase 3   EUCTR2018-002722-22-DE   Belgium;France;Germany;Ireland;Italy;Netherlands;United Kingdom
      2019   Phase 3   EUCTR2018-002722-22-BE   Belgium;Germany;Italy;Netherlands;United Kingdom
   ISTITUTO NEUROLOGICO CARLO BESTA
      2008   -   EUCTR2007-001592-10-IT   Italy
   Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
      2021   -   ChiCTR2100051913   China
Taurursodiol
   AMYLYX PHARMACEUTICALS Inc.
      2022   Phase 3   EUCTR2022-002348-33-IT   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2021   Phase 3   EUCTR2021-000250-26-IT   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
   Amylyx Pharmaceuticals Inc.
      2023   Phase 3   EUCTR2022-002348-33-PT   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2023   Phase 3   EUCTR2022-002348-33-PL   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2023   Phase 3   EUCTR2022-002348-33-FR   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2023   Phase 3   EUCTR2022-002348-33-BE   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2022   Phase 3   EUCTR2022-002348-33-NL   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2022   Phase 3   EUCTR2022-002348-33-ES   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-000250-26-PT   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-000250-26-PL   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-000250-26-BE   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2021   Phase 3   EUCTR2021-000250-26-SE   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2021   Phase 3   EUCTR2021-000250-26-NL   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2021   Phase 3   EUCTR2021-000250-26-FR   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2021   Phase 3   EUCTR2021-000250-26-ES   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2021   Phase 3   EUCTR2021-000250-26-DE   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
TCD601
   ITB-Med LLC
      2024   Phase 1   NCT06453668   Sweden
TCH346
   NOVARTIS FARMA
      2004   -   EUCTR2004-002855-15-IT   Germany;Italy;United Kingdom
   Novartis
      2004   Phase 2   NCT00230074   United States
   Novartis Pharma Services AG
      2004   -   EUCTR2004-002855-15-GB   Germany;Italy;United Kingdom
      2004   -   EUCTR2004-002855-15-DE   Germany;Italy;United Kingdom
   Novartis Pharmaceuticals
      2003   Phase 2   NCT00072709   Belgium;Canada;France;Germany;Italy;Netherlands;Switzerland;United Kingdom;United States
      2002   Phase 2   NCT00036413   United States
Tenofovir alafenamide
   National Institute of Neurological Disorders and Stroke (NINDS)
      2019   Phase 1   NCT02437110   United States
Testosterone
   National Center for Research Resources (NCRR)
      1992   Phase 2   NCT00004771   -
Tevagrastim
   Università degli Studi di Torino e Azienda Ospedaliera Città della Salute e della Scienza di Torino
      2014   Phase 2   EUCTR2014-002228-28-IT   Italy
Thalidomide
   Charite University, Berlin, Germany
      2005   Phase 2   NCT00231140   Germany
   Dartmouth-Hitchcock Medical Center
      2005   Phase 2   NCT00140452   United States
THE center FOR neurologic studies bulbar function scale
   University of Florida
      2016   Early Phase 1   NCT02710162   United States
THE center FOR neurologic study bulbar function scale
   University of Florida
      2017   -   NCT02962050   United States
THE study drug IS SHED-CM manufactured BY U-factor
   Hitonowa Medical
      2024   Early Phase 1   NCT06889857   Japan
      2023   -   NCT06608719   Japan
Theracurmin HP
   Richard Bedlack, M.D., Ph.D.
      2020   Phase 2   NCT04499963   United States
Tideglusib
   University of Zurich
      2025   Phase 2   NCT05105958   Switzerland
Tioctic acid
   AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO
      2006   -   EUCTR2005-005152-40-IT   Italy
Tirasemtiv
   CYTOKINETICS, INC.
      2017   Phase 3   EUCTR2016-002629-13-IT   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2014-005413-23-IT   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States
   Cytokinetics
      2016   Phase 3   NCT02936635   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States
      2015   Phase 3   NCT02496767   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States
   Cytokinetics Inc
      2013   -   EUCTR2012-004987-23-IE   Canada;Germany;Ireland;Netherlands;Spain;United Kingdom;United States
      2013   Phase 2   EUCTR2012-004987-23-GB   Canada;Germany;Ireland;Netherlands;Spain;United Kingdom;United States
      2013   Phase 2   EUCTR2012-004987-23-ES   Canada;France;Germany;Ireland;Netherlands;Spain;United Kingdom;United States
      2013   -   EUCTR2012-004987-23-DE   Canada;Germany;Ireland;Netherlands;Spain;United Kingdom;United States
      -   -   EUCTR2012-004987-23-NL   Canada;France;Germany;Ireland;Netherlands;Spain;United Kingdom;United States
   Cytokinetics, Inc.
      2017   Phase 3   EUCTR2016-002629-13-PT   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002629-13-NL   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002629-13-IE   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002629-13-GB   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002629-13-FR   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002629-13-ES   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002629-13-BE   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2014-005413-23-PT   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2014-005413-23-NL   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2014-005413-23-IE   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2014-005413-23-ES   Belgium;Canada;France;Germany;Ireland;Netherlands;Portugal;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2014-005413-23-DE   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2014-005413-23-BE   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States
      2015   Phase 3   EUCTR2014-005413-23-GB   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States
TJ-68
   Hiroshi Mitsumoto
      2022   Phase 1/Phase 2   NCT04998305   United States
Tocilizumab
   Barrow Neurological Institute
      2015   Phase 2   NCT02469896   United States
Tocotrienols
   University of Malaya
      2019   Phase 2   NCT04140136   Malaysia
Tofacitinib tablets
   Beijing Tiantan Hospital
      2024   Early Phase 1   NCT06689982   China
Tofersen
   BIOGEN IDEC RESEARCH LIMITED
      2022   Phase 3   EUCTR2020-004590-51-IT   Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
   Biogen
      2024   -   NCT04972487   United States
      2021   Phase 3   NCT04856982   Australia;Belgium;Brazil;Canada;France;Germany;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   NCT03070119   Belgium;Canada;France;Germany;Italy;Japan;New Zealand;United Kingdom;United States
   Biogen Idec Research Limited
      2021   Phase 3   EUCTR2020-004590-51-FR   Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004590-51-ES   Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004590-51-DE   Australia;Belgium;Brazil;Canada;France;Germany;Italy;Japan;Korea, Republic of;Poland;Spain;Sweden;United Kingdom;United States
      2021   Phase 3   EUCTR2016-003225-41-ES   Australia;Belgium;Canada;Denmark;European Union;Germany;Israel;Italy;Japan;New Zealand;Poland;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2016-003225-41-DK   Australia;Belgium;Canada;Denmark;European Union;Germany;Israel;Italy;Japan;New Zealand;Poland;Spain;United Kingdom;United States
      2020   Phase 1;Phase 2;Phase 3   EUCTR2015-004098-33-DK   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Poland;Sweden;United Kingdom;United States
      2018   Phase 3   EUCTR2016-003225-41-DE   Australia;Belgium;Canada;Denmark;European Union;Germany;Israel;Italy;Japan;New Zealand;Poland;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-003225-41-BE   Australia;Belgium;Canada;Denmark;European Union;Germany;Israel;Italy;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States
   Cho Kyo
      2024   -   JPRN-jRCT2071240022   -
TP04hn106
   Talengen Institute of Life Sciences, Shenzhen, P.R. China.
      2024   Phase 1/Phase 2   NCT06726577   China
TPN-101
   Transposon Therapeutics, Inc
      2022   Phase 2   EUCTR2021-002251-11-FR   Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-002251-11-ES   Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-002251-11-BE   Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States
      2021   Phase 2   EUCTR2021-002251-11-DE   Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States
TPN-101, 400 MG/DAY
   Transposon Therapeutics, Inc.
      2021   Phase 2   NCT04993755   Belgium;France;Germany;Netherlands;Spain;United States
Trametinib
   Genuv Inc.
      2020   Phase 1/Phase 2   NCT04326283   Korea, Republic of
Trazodone hydrochloride oral solution
   University of Edinburgh
      2020   Phase 2/Phase 3   NCT04302870   United Kingdom
Trehalose
   Seelos Therapeutics, Inc.
      2023   -   NCT05597436   United States
Tretinoin and pioglitazone HCL
   Phoenix Neurological Associates, LTD
      2008   Phase 1/Phase 2   NCT00919555   United States
Triheptanoin
   Richard Bedlack, M.D., Ph.D.
      2018   Phase 1/Phase 2   NCT03506425   United States
Trimetazidine
   The University of Queensland
      2021   Phase 2   EUCTR2020-005018-17-NL   Australia;Netherlands
Trimetazidine dihydrochloride
   The University of Queensland
      2021   Phase 2   NCT04788745   Australia;Netherlands;United Kingdom
Triumeq
   Macquarie University, Australia
      2024   Phase 3   NCT06658977   Australia
   Neuroscience Trials Australia
      2016   Phase 2   NCT02868580   Australia
   Stichting TRICALS Foundation
      2023   Phase 3   EUCTR2020-005069-15-SI   Australia;Ireland;Netherlands;Slovenia;Spain;United Kingdom
      2022   Phase 3   EUCTR2020-005069-15-IE   Australia;Ireland;Netherlands;Slovenia;Spain;United Kingdom
      2021   Phase 3   EUCTR2020-005069-15-NL   Australia;Ireland;Netherlands;Slovenia;Spain;United Kingdom
TRO19622
   Hoffmann-La Roche
      2010   Phase 2/Phase 3   NCT01285583   Belgium;France;Germany;Spain;United Kingdom
   TROPHOS
      2011   -   EUCTR2010-021179-10-GB   Germany;Spain;United Kingdom
      2009   Phase 2;Phase 3   EUCTR2008-007320-25-GB   Belgium;France;Germany;Spain;United Kingdom
   TROPHOS SA
      2011   -   EUCTR2010-021179-10-DE   Germany;Spain;United Kingdom
      2011   Phase 2;Phase 3   EUCTR2010-021179-10-BE   Belgium;Germany;Spain;United Kingdom
      2009   Phase 2;Phase 3   EUCTR2008-007320-25-FR   Belgium;France;Germany;Spain;United Kingdom
      2009   Phase 2   EUCTR2008-007320-25-ES   Belgium;France;Germany;Spain;United Kingdom
      2009   -   EUCTR2008-007320-25-DE   Belgium;France;Germany;Spain;United Kingdom
      2009   Phase 2;Phase 3   EUCTR2008-007320-25-BE   Belgium;France;Germany;Spain;United Kingdom
Trobalt
   Centre for Human Drug Research
      2015   Phase 2   EUCTR2015-001431-20-NL   Netherlands
Tudca
   Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
      2008   Phase 2   NCT00877604   Italy
   Humanitas Mirasole SpA
      2019   Phase 3   EUCTR2018-002722-22-NL   Belgium;France;Germany;Italy;Netherlands;United Kingdom
      2019   Phase 3   EUCTR2018-002722-22-IE   Belgium;France;Germany;Ireland;Italy;Netherlands;United Kingdom
      2019   Phase 3   EUCTR2018-002722-22-FR   Belgium;France;Germany;Italy;Netherlands;United Kingdom
      2019   Phase 3   EUCTR2018-002722-22-DE   Belgium;France;Germany;Ireland;Italy;Netherlands;United Kingdom
      2019   Phase 3   EUCTR2018-002722-22-BE   Belgium;Germany;Italy;Netherlands;United Kingdom
   IRCCS ISTITUTO CLINICO HUMANITAS
      2018   Phase 3   EUCTR2018-002722-22-IT   Belgium;France;Germany;Ireland;Italy;Netherlands;United Kingdom
Tudcabil
   Humanitas Mirasole SpA
      2019   Phase 3   EUCTR2018-002722-22-NL   Belgium;France;Germany;Italy;Netherlands;United Kingdom
      2019   Phase 3   EUCTR2018-002722-22-IE   Belgium;France;Germany;Ireland;Italy;Netherlands;United Kingdom
      2019   Phase 3   EUCTR2018-002722-22-FR   Belgium;France;Germany;Italy;Netherlands;United Kingdom
      2019   Phase 3   EUCTR2018-002722-22-DE   Belgium;France;Germany;Ireland;Italy;Netherlands;United Kingdom
      2019   Phase 3   EUCTR2018-002722-22-BE   Belgium;Germany;Italy;Netherlands;United Kingdom
   IRCCS ISTITUTO CLINICO HUMANITAS
      2018   Phase 3   EUCTR2018-002722-22-IT   Belgium;France;Germany;Ireland;Italy;Netherlands;United Kingdom
TV-7110
   Teva Pharmaceutical Industries, Ltd
      2008   -   EUCTR2008-002062-62-NL   Belgium;France;Germany;Hungary;Italy;Netherlands;Spain
      2008   -   EUCTR2008-002062-62-HU   Belgium;France;Germany;Hungary;Italy;Netherlands;Spain
      2008   Phase 2   EUCTR2008-002062-62-FR   Belgium;France;Germany;Hungary;Italy;Netherlands;Spain
      2008   Phase 2   EUCTR2008-002062-62-ES   Belgium;France;Germany;Hungary;Italy;Netherlands;Spain
      2008   -   EUCTR2008-002062-62-DE   Belgium;France;Germany;Hungary;Italy;Netherlands;Spain
      2008   -   EUCTR2008-002062-62-BE   Belgium;France;Germany;Hungary;Italy;Netherlands;Spain
   Teva Pharmaceutical Industries,Ltd
      2008   -   EUCTR2008-002062-62-IT   Belgium;France;Germany;Hungary;Italy;Netherlands;Spain
Téralithe LP
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2008   -   EUCTR2008-003707-32-FR   France
Ulefnersen
   Ionis Pharmaceuticals, Inc.
      2021   Phase 1;Phase 2;Phase 3   EUCTR2020-005522-28-BE   Belgium;Brazil;Canada;Germany;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      -   Phase 1;Phase 2;Phase 3   EUCTR2020-005522-28-SE   Belgium;Brazil;Canada;Germany;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
      -   Phase 1;Phase 2;Phase 3   EUCTR2020-005522-28-PL   Belgium;Brazil;Canada;Germany;Ireland;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      -   Phase 1;Phase 2;Phase 3   EUCTR2020-005522-28-IE   Belgium;Brazil;Canada;Germany;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
Ultomiris
   ALEXION PHARMACEUTICALS INCORPORATED
      2020   Phase 3   EUCTR2019-004619-30-IT   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
   Alexion Pharmaceuticals
      2020   Phase 3   EUCTR2019-004619-30-SE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004619-30-NL   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004619-30-IE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004619-30-GB   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004619-30-FR   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004619-30-ES   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004619-30-DK   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004619-30-DE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
Ultra-HIGH-caloric carbohydrate-rich diet
   Albert Christian Ludolph, Prof.
      2019   Phase 1   NCT04172792   Germany
Ultra-HIGH-caloric fatty diet
   Albert Christian Ludolph, Prof.
      2019   Phase 1   NCT04172792   Germany
   University of Ulm
      2024   -   NCT06280079   Germany
Umbilical cord blood therapy
   MinYoung Kim, M.D.
      2014   -   NCT02236065   Korea, Republic of
Ursodoxicoltaurina
   Amylyx Pharmaceuticals Inc.
      2021   Phase 3   EUCTR2021-000250-26-ES   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
Ursodoxicoltaurine
   Amylyx Pharmaceuticals Inc.
      2023   Phase 3   EUCTR2022-002348-33-PT   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2023   Phase 3   EUCTR2022-002348-33-PL   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2023   Phase 3   EUCTR2022-002348-33-FR   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2023   Phase 3   EUCTR2022-002348-33-BE   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2022   Phase 3   EUCTR2022-002348-33-NL   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2022   Phase 3   EUCTR2022-002348-33-ES   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-000250-26-PT   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-000250-26-PL   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-000250-26-BE   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2021   Phase 3   EUCTR2021-000250-26-SE   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2021   Phase 3   EUCTR2021-000250-26-NL   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2021   Phase 3   EUCTR2021-000250-26-FR   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2021   Phase 3   EUCTR2021-000250-26-DE   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
Ursodoxycoltaurine
   AMYLYX PHARMACEUTICALS Inc.
      2022   Phase 3   EUCTR2022-002348-33-IT   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
Utreloxastat
   PTC Therapeutics, Inc.
      2023   Phase 2   EUCTR2021-006511-29-SE   Argentina;Australia;Belgium;Brazil;Czech Republic;Czechia;France;Germany;Ireland;Italy;Japan;Mexico;Netherlands;Norway;Poland;Spain;Sweden;United States
      2023   Phase 2   EUCTR2021-006511-29-NO   Argentina;Australia;Belgium;Brazil;Czech Republic;Czechia;France;Germany;Ireland;Italy;Japan;Mexico;Netherlands;Norway;Poland;Spain;Sweden;United States
      2023   Phase 2   EUCTR2021-006511-29-NL   Argentina;Australia;Belgium;Brazil;Czech Republic;Czechia;France;Germany;Ireland;Italy;Japan;Mexico;Netherlands;Norway;Poland;Spain;Sweden;United States
      2023   Phase 2   EUCTR2021-006511-29-CZ   Argentina;Australia;Belgium;Brazil;Czech Republic;Czechia;France;Germany;Ireland;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Spain;Sweden;United States
      2022   Phase 2   EUCTR2021-006511-29-DE   Argentina;Australia;Belgium;Brazil;Czech Republic;Czechia;France;Germany;Ireland;Italy;Japan;Mexico;Netherlands;Norway;Poland;Spain;Sweden;United States
      2022   Phase 2   EUCTR2021-006511-29-BE   Argentina;Australia;Belgium;Brazil;Czech Republic;Czechia;France;Germany;Ireland;Italy;Japan;Mexico;Netherlands;Norway;Poland;Spain;Sweden;United States
Vastarel
   The University of Queensland
      2021   Phase 2   EUCTR2020-005018-17-NL   Australia;Netherlands
VGN-R13
   Hong Chen
      2025   Early Phase 1   NCT06849609   China
VHB937
   Novartis Pharmaceuticals
      2024   Phase 2   NCT06643481   United States
Videofluoroscopic swallowing study
   University of Florida
      2017   -   NCT02962050   United States
      2016   Early Phase 1   NCT02710162   United States
      2016   Early Phase 1   NCT02710110   United States
Vitamin E
   Lawson Health Research Institute
      2006   Phase 3   NCT00372879   Canada
VM202
   Helixmith Co., Ltd.
      2014   Phase 1/Phase 2   NCT02039401   United States
Voluntary peak cough flow testing
   University of Florida
      2017   -   NCT02962050   United States
VRG50635
   Verge Genomics
      2024   Phase 1   NCT06215755   Belgium;Canada;Finland;Netherlands
Water
   Clinical Research Hospital Tokyo
      2014   -   JPRN-UMIN000015054   Japan
   First Affiliated Hospital of Harbin Medical University
      2025   Phase 1   ChiCTR2500101605   China
   National Hospital Organization Takasaki General Medical Center
      2015   -   JPRN-UMIN000019111   Japan
Wharton’S jelly-derived mesenchymal stem cells
   Polski Bank Komórek Macierzystych JSC (PBKM)
      2020   Phase 1;Phase 2   EUCTR2018-004171-12-PL   Poland
Whole exome sequencing
   Neuromed IRCCS
      2025   -   NCT06803784   Italy
Whole genome sequencing
   Neuromed IRCCS
      2025   -   NCT06803784   Italy
Withania somnifera
   Sunnybrook Health Sciences Centre
      2021   Phase 2   NCT05031351   Canada
WVE-004
   Wave Life Sciences Ltd.
      2022   Phase 1/Phase 2   NCT05683860   Netherlands;United Kingdom
      2021   Phase 1/Phase 2   NCT04931862   Australia;Belgium;Canada;Ireland;Netherlands;New Zealand;Sweden;United Kingdom
   Wave Life Sciences UK Limited
      2023   Phase 1;Phase 2   EUCTR2022-002267-29-BE   Australia;Belgium;Canada;Ireland;Netherlands;New Zealand;United Kingdom
      2022   Phase 1;Phase 2   EUCTR2020-005193-94-SE   Australia;Belgium;Canada;Germany;Ireland;Netherlands;New Zealand;Sweden;United Kingdom;United States
      2022   Phase 1;Phase 2   EUCTR2020-005193-94-BE   Australia;Belgium;Canada;Germany;Ireland;Netherlands;New Zealand;Sweden;United Kingdom;United States
      2021   Phase 1;Phase 2   EUCTR2020-005193-94-DE   Australia;Belgium;Canada;Germany;Ireland;Netherlands;New Zealand;Sweden;United Kingdom;United States
XT-150
   Xalud Therapeutics, Inc.
      2025   Phase 1   NCT06704347   United States
YAM80
   Yoshino Neurology Clinic
      2009   Phase 2   NCT00886977   Japan
Zibren*20bust 500MG
   IST. DI RICERCHE FARMACOLOG. M. NEGRI
      2005   -   EUCTR2004-004158-23-IT   Italy
Zinc and copper
   Phoenix Neurological Associates, LTD
      2010   Phase 1/Phase 2   NCT01259050   United States
ZYIL1 capsules 25 MG and ZYIL1 capsules 50 MG
   Zydus Lifesciences Limited
      2023   Phase 2   NCT05981040   India
Zyprexa
   Charité – Universitätsmedizin Berlin
      2008   -   EUCTR2007-003775-39-DE   Germany